[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 6147
1. Ohata S, Moriyama C, Yamashita A, Nishida T, Kusumoto C, Mochida S, Minami Y, Nakada J, Shomori K, Inagaki Y, Ohta Y, Matsura T: Polaprezinc Protects Mice against Endotoxin Shock. J Clin Biochem Nutr; 2010 May;46(3):234-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we investigated whether PZ suppresses mortality, pulmonary inflammation, and plasma nitric oxide (NO) and tumor necrosis factor (TNF)-alpha levels in endotoxin shock mice after peritoneal injection of lipopolysaccharide (LPS), and how PZ protects against LPS-induced endotoxin shock.

  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mediators Inflamm. 2009;2009:729172 [19727408.001]
  • [Cites] Digestion. 2009;79(4):243-50 [19401612.001]
  • [Cites] Biochem Pharmacol. 2009 Aug 1;78(3):301-14 [19376089.001]
  • [Cites] J Radiat Res. 2008 Jul;49(4):341-7 [18413982.001]
  • [Cites] J Clin Biochem Nutr. 2007 Sep;41(2):115-23 [18193105.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2007 Nov;146(4):443-59 [17716951.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):4180-6 [17785857.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7301-7 [17671199.001]
  • [Cites] J Nutr. 2007 May;137(5):1345-9 [17449604.001]
  • [Cites] Life Sci. 2006 Nov 10;79(24):2245-50 [16949620.001]
  • [Cites] World J Gastroenterol. 2006 Oct 14;12(38):6178-81 [17036391.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Nov;21(11):1669-74 [16984587.001]
  • [Cites] J Pineal Res. 2006 Oct;41(3):211-9 [16948781.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Aug 18;347(1):297-300 [16815296.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Apr;290(4):L622-L645 [16531564.001]
  • [Cites] Toxicology. 2006 Feb 15;219(1-3):187-96 [16377054.001]
  • [Cites] Life Sci. 2006 Jan 2;78(6):571-7 [16107265.001]
  • [Cites] Scand J Gastroenterol. 2005 Nov;40(11):1321-7 [16334442.001]
  • [Cites] Shock. 2005 Nov;24(5):482-7 [16247336.001]
  • [Cites] J Surg Res. 2005 Nov;129(1):90-3 [16139305.001]
  • [Cites] J Pineal Res. 2005 Nov;39(4):400-8 [16207296.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Jul;133(1):70-9 [16025056.001]
  • [Cites] Immunity. 2005 Jan;22(1):93-104 [15664162.001]
  • [Cites] Microbiol Immunol. 2004;48(12):957-63 [15611612.001]
  • [Cites] Thorax. 2004 Dec;59(12):1057-62 [15563705.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Oct;291(1):345-52 [10490923.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Apr 7;245(1):33-7 [9535778.001]
  • [Cites] Shock. 1997 Apr;7(4):254-62 [9110410.001]
  • [Cites] Biochim Biophys Acta. 1991 Nov 14;1115(1):15-22 [1659910.001]
  • [Cites] Free Radic Res Commun. 1991;14(4):289-96 [1874458.001]
  • [Cites] Dig Dis Sci. 1990 May;35(5):559-66 [2331952.001]
  • [Cites] Jpn J Pharmacol. 1990 Apr;52(4):513-21 [2342223.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Clin Biochem Nutr. 2010 Jan;46(1):43-51 [20104264.001]
  • [Cites] Free Radic Biol Med. 2004 Oct 15;37(8):1182-90 [15451058.001]
  • [Cites] Immunology. 2004 Oct;113(2):153-62 [15379975.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1547-56 [15111301.001]
  • [Cites] J Pharmacol Exp Ther. 2004 May;309(2):670-6 [14747614.001]
  • [Cites] Drug Metab Dispos. 2003 Dec;31(12):1499-506 [14625346.001]
  • [Cites] Curr Opin Immunol. 2003 Feb;15(1):5-11 [12495726.001]
  • [Cites] Circulation. 2002 Nov 12;106(20):2601-7 [12427658.001]
  • [Cites] Cytokine. 2001 Dec 21;16(6):210-9 [11884024.001]
  • [Cites] Eur J Pharmacol. 2001 Dec 21;433(2-3):177-85 [11755151.001]
  • [Cites] Shock. 2001 Aug;16(2):83-96 [11508871.001]
  • [Cites] Jpn J Pharmacol. 2000 Sep;84(1):63-70 [11043455.001]
  • [Cites] Proc Soc Exp Biol Med. 2000 Jun;224(2):102-8 [10806417.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1334-49 [10793167.001]
  • (PMID = 20490319.001).
  • [ISSN] 1880-5086
  • [Journal-full-title] Journal of clinical biochemistry and nutrition
  • [ISO-abbreviation] J Clin Biochem Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2872229
  • [Keywords] NOTNLM ; heat shock protein / inducible nitric oxide synthase / lipopolysaccharide / nuclear factor-κB / polaprezinc
  •  go-up   go-down


2. Zhou QH, Wu C, Manickam DS, Oupický D: Evaluation of pharmacokinetics of bioreducible gene delivery vectors by real-time PCR. Pharm Res; 2009 Jul;26(7):1581-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pharmacokinetic parameters in tumor-bearing mice were analyzed by PKAnalyst.

  • COS Scholar Universe. author profiles.
  • NCI caNanoLab Data Portal. supplemental materials - caNanoLab samples curated from the publication .
  • Hazardous Substances Data Bank. HYDROXYPROPYL METHACRYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioconjug Chem. 2000 Jul-Aug;11(4):492-501 [10898570.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(1):e4 [19004870.001]
  • [Cites] Pharm Res. 2001 Jan;18(1):67-74 [11336355.001]
  • [Cites] Vaccine. 2001 Aug 14;19(31):4519-25 [11483279.001]
  • [Cites] Gene Ther. 2001 Oct;8(20):1587-92 [11704820.001]
  • [Cites] J Pharm Sci. 2001 Dec;90(12):2010-22 [11745760.001]
  • [Cites] J Am Chem Soc. 2002 Jan 9;124(1):8-9 [11772047.001]
  • [Cites] Methods Enzymol. 2002;348:200-15 [11885273.001]
  • [Cites] Mol Ther. 2002 Apr;5(4):463-72 [11945074.001]
  • [Cites] J Gene Med. 2002 Sep-Oct;4(5):536-47 [12221647.001]
  • [Cites] Biochem Pharmacol. 2002 Nov 15;64(10):1533-46 [12417266.001]
  • [Cites] Biomed Pharmacother. 2003 May-Jun;57(3-4):145-55 [12818476.001]
  • [Cites] J Agric Food Chem. 2003 Nov 5;51(23):6676-82 [14582959.001]
  • [Cites] AAPS PharmSciTech. 2000;1(2):E11 [14727844.001]
  • [Cites] BJU Int. 2004 Mar;93(4):465-9 [15008710.001]
  • [Cites] Annu Rev Biochem. 1983;52:711-60 [6137189.001]
  • [Cites] Stereotact Funct Neurosurg. 1990;54-55:290-6 [2080344.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4412-6 [1584774.001]
  • [Cites] Z Naturforsch C. 1992 Nov-Dec;47(11-12):910-4 [1285830.001]
  • [Cites] J Pharm Sci. 1996 Jun;85(6):612-8 [8773958.001]
  • [Cites] J Am Soc Mass Spectrom. 1998 Mar;9(3):194-201 [9879356.001]
  • [Cites] Gene Ther. 1999 Apr;6(4):643-50 [10476224.001]
  • [Cites] Radiat Res. 1963 May;19:42-9 [13975318.001]
  • [Cites] Radiology. 2005 May;235(2):541-6 [15798154.001]
  • [Cites] Rapid Commun Mass Spectrom. 2005;19(12):1675-82 [15912467.001]
  • [Cites] J Control Release. 2005 Sep 2;106(3):416-27 [15967534.001]
  • [Cites] J Exp Bot. 2006;57(7):1509-14 [16551682.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2006 Oct;61(10):1030-8 [17077195.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:191-6 [17108211.001]
  • [Cites] J Control Release. 2007 Mar 12;118(1):118-25 [17250923.001]
  • [Cites] Bioconjug Chem. 2008 Jan;19(1):244-53 [18034452.001]
  • [Cites] Anal Biochem. 2008 Aug 1;379(1):96-104 [18501185.001]
  • [Cites] J Nucl Med. 2008 Nov;49(11):1828-35 [18927335.001]
  • [Cites] Biochim Biophys Acta. 2000 Sep 1;1523(1):103-10 [11099863.001]
  • (PMID = 19240986.001).
  • [ISSN] 1573-904X
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109711; United States / NCI NIH HHS / CA / CA 109711
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylamides; 0 / Disulfides; 0 / Methacrylates; 0 / Oligopeptides; 0 / Polyamines; 0 / polycations; 21442-01-3 / N-(2-hydroxypropyl)methacrylamide; 27813-02-1 / hydroxypropyl methacrylate; 9007-49-2 / DNA; 99896-85-2 / arginyl-glycyl-aspartic acid
  • [Other-IDs] NLM/ NIHMS521465; NLM/ PMC3810963
  •  go-up   go-down


3. de Parades V, Bauer P, Benbunan JL, Bouillet T, Cottu PH, Cuenod CA, Durdux C, Fléjou JF, Atienza P: [Initial pretherapeutic assessment of anal epidermoid carcinoma]. Gastroenterol Clin Biol; 2007 Feb;31(2):157-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Initial pretherapeutic assessment of anal epidermoid carcinoma].
  • [Transliterated title] Bilan préthérapeutique initial du carcinome épidermoïde invasif de l'anus.
  • Anal epidermoid carcinoma is a rare malignant tumor, comprising less than 5% of all carcinomas of the colon, rectum, and anus.
  • In addition, magnetic resonance imaging, positron emission tomography scanning and inguinal sentinel lymph node procedure should play a role in a more selective approach in patients with anal carcinoma.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Diagnostic Imaging. Humans. Neoplasm Staging. Risk Factors

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347624.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 96
  •  go-up   go-down


Advertisement
4. Kim KA, Spencer SL, Albeck JG, Burke JM, Sorger PK, Gaudet S, Kim DH: Systematic calibration of a cell signaling network model. BMC Bioinformatics; 2010;11:202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address this problem, we developed a systematic methodology for calibrating quantitative models of dynamic biological processes and illustrate its utility by validating a model of TRAIL (Tumor necrosis factor Related Apoptosis-Inducing Ligand)-induced cell death.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Risk Anal. 2002 Jun;22(3):553-78 [12088234.001]
  • [Cites] Annu Rev Biomed Eng. 2000;2:31-53 [11701506.001]
  • [Cites] Genome Res. 2003 Nov;13(11):2467-74 [14559783.001]
  • [Cites] J Cell Biol. 2004 Sep 13;166(6):839-51 [15364960.001]
  • [Cites] Nature. 1997 Jul 17;388(6639):300-4 [9230442.001]
  • [Cites] Bioinformatics. 1998;14(10):869-83 [9927716.001]
  • [Cites] FEBS Lett. 2005 Feb 14;579(5):1101-8 [15710397.001]
  • [Cites] FEBS Lett. 2005 Mar 21;579(8):1846-53 [15763562.001]
  • [Cites] Biosystems. 2006 Feb-Mar;83(2-3):248-65 [16236429.001]
  • [Cites] Syst Biol (Stevenage). 2006 Jul;153(4):201-11 [16986622.001]
  • [Cites] Nat Cell Biol. 2006 Nov;8(11):1195-203 [17060902.001]
  • [Cites] J Theor Biol. 2009 Dec 21;261(4):511-30 [19665034.001]
  • [Cites] PLoS Biol. 2008 Dec 2;6(12):2831-52 [19053173.001]
  • [Cites] Nature. 2009 May 21;459(7245):428-32 [19363473.001]
  • [Cites] Nat Biotechnol. 2000 Nov;18(11):1147-50 [11062431.001]
  • [Cites] Curr Opin Cell Biol. 2003 Apr;15(2):221-31 [12648679.001]
  • (PMID = 20416044.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / P50 GM068762
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TNF-Related Apoptosis-Inducing Ligand
  •  go-up   go-down


5. Andrade FH, Figueiroa FC, Bersano PR, Bissacot DZ, Rocha NS: Malignant mammary tumor in female dogs: environmental contaminants. Diagn Pathol; 2010;5:45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mammary tumor in female dogs: environmental contaminants.
  • Mammary tumors of female dogs have greatly increased in recent years, thus demanding rapid diagnosis and effective treatment in order to determine the animal survival.
  • There is considerable scientific interest in the possible role of environmental contaminants in the etiology of mammary tumors, specifically in relation to synthetic chemical substances released into the environment to which living beings are either directly or indirectly exposed.
  • In this study, the presence of pyrethroid insecticide was observed in adjacent adipose tissue of canine mammary tumor.
  • High Precision Liquid Chromatography - HPLC was adapted to detect and identify environmental contaminants in adipose tissue adjacent to malignant mammary tumor in nine female dogs, without predilection for breed or age.
  • After surgery, masses were carefully examined for malignant neoplastic lesions.
  • Five grams of adipose tissue adjacent to the tumor were collected to detect of environmental contaminants.
  • From these tumors, seven (77.8%) presented aggressiveness degree III and two (22.2%) degree I.
  • Five tumors were positive for estrogen receptors in immunohistochemical analysis.
  • The contamination level was observed in more aggressive tumors.
  • This was the first report in which the level of environmental contaminants could be detected in adipose tissue of female dogs with malignant mammary tumor, by HPLC.
  • Results suggest the possible involvement of pyrethroid in the canine mammary tumor carcinogenesis.
  • [MeSH-major] Carcinogens, Environmental / adverse effects. Carcinoma / chemically induced. Dog Diseases / chemically induced. Insecticides / adverse effects. Mammary Glands, Animal / drug effects. Mammary Neoplasms, Animal / chemically induced. Pyrethrins / adverse effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2000 Mar;21(3):427-33 [10688862.001]
  • [Cites] Prev Vet Med. 2000 Nov 16;47(3):187-204 [11058779.001]
  • [Cites] Cancer Lett. 2002 Jul 26;181(2):179-86 [12175533.001]
  • [Cites] J Natl Cancer Inst. 1969 Dec;43(6):1249-61 [4319248.001]
  • [Cites] Bull World Health Organ. 1971;44(1-3):11-22 [5315342.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Oct 29;251(3):855-9 [9790999.001]
  • [Cites] J Comp Pathol. 1989 Nov;101(4):389-97 [2558128.001]
  • [Cites] J Reprod Fertil Suppl. 1993;47:483-7 [8229967.001]
  • [Cites] Diagn Cytopathol. 1995 Nov;13(4):347-51 [8599924.001]
  • [Cites] J Anal Toxicol. 1997 Sep;21(5):397-402 [9288595.001]
  • [Cites] Vet Pathol. 1983 Mar;20(2):127-42 [6836870.001]
  • (PMID = 20587072.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens, Environmental; 0 / Insecticides; 0 / Pyrethrins
  • [Other-IDs] NLM/ PMC2909155
  •  go-up   go-down


6. Walji R, Boon H, Guns E, Oneschuk D, Younus J: Black cohosh (Cimicifuga racemosa [L.] Nutt.): safety and efficacy for cancer patients. Support Care Cancer; 2007 Aug;15(8):913-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With relevance to cancer patients, black cohosh also seems not to exhibit phytoestrogenic activity and is in fact possibly an inhibitor of tumor growth.
  • CONCLUSIONS: The use of black cohosh appears to be safe in breast cancer patients without risk for liver disease, although further research is needed in this and other populations.
  • [MeSH-major] Breast Neoplasms / drug therapy. Cimicifuga. Phytotherapy / contraindications. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2004 Feb;83(3):221-31 [14758092.001]
  • [Cites] Med Decis Making. 2003 Nov-Dec;23(6):471-9 [14672107.001]
  • [Cites] Toxicol Lett. 2004 May 2;150(3):271-5 [15110078.001]
  • [Cites] Maturitas. 2000 Oct 31;36(3):155-64 [11063896.001]
  • [Cites] Menopause. 2002 Mar-Apr;9(2):145-50 [11875334.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1407-12 [14532983.001]
  • [Cites] Planta Med. 2007 Feb;73(2):184-7 [17295185.001]
  • [Cites] Maturitas. 2003 Mar 14;44 Suppl 1:S59-65 [12609560.001]
  • [Cites] Prostate. 2006 Oct 1;66(14):1512-20 [16921512.001]
  • [Cites] Maturitas. 2003 Mar 14;44 Suppl 1:S39-50 [12609558.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2836-41 [16782922.001]
  • [Cites] J Nat Prod. 2006 Mar;69(3):314-8 [16562825.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Jan;80(1):125-30 [11867271.001]
  • [Cites] Urology. 2003 Nov;62(5):849-53 [14624907.001]
  • [Cites] Eur Urol. 1994;26(2):120-2 [7957465.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1275-84 [16985246.001]
  • [Cites] Integr Cancer Ther. 2006 Jun;5(2):117-22 [16685076.001]
  • [Cites] Oncol Res. 2005;15(5):281-9 [16261847.001]
  • [Cites] Nutr Cancer. 2006;56(1):3-10 [17176212.001]
  • [Cites] Support Care Cancer. 2005 Oct;13(10):806-11 [15711946.001]
  • [Cites] Cancer Invest. 2004;22(4):515-21 [15565808.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2515-21 [10893281.001]
  • [Cites] Oncologist. 2006 Jul-Aug;11(7):732-41 [16880232.001]
  • [Cites] Eur J Cancer Care (Engl). 2006 Sep;15(4):362-8 [16968318.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):259-68 [12711012.001]
  • [Cites] Med Hypotheses. 1991 Aug;35(4):349-50 [1943887.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2739-45 [11352967.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4077-9 [12970265.001]
  • [Cites] Ann Med. 2005;37(6):423-38 [16203615.001]
  • [Cites] J Support Oncol. 2006 Jul-Aug;4(7):315-20, 325 [16892692.001]
  • [Cites] Ann Intern Med. 2006 Mar 7;144(5):364-7 [16520478.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3448-52 [12067987.001]
  • [Cites] J Altern Complement Med. 2006 Oct;12(8):805-12 [17034287.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):995-1015 [17158751.001]
  • [Cites] J Agric Food Chem. 2002 Nov 20;50(24):7022-8 [12428954.001]
  • [Cites] Planta Med. 2006 May;72(6):521-6 [16773536.001]
  • [Cites] Menopause. 2004 May-Jun;11(3):281-9 [15167307.001]
  • [Cites] Qual Health Res. 1999 Sep;9(5):639-53 [10558372.001]
  • [Cites] J Agric Food Chem. 2001 May;49(5):2472-9 [11368622.001]
  • [Cites] J Altern Complement Med. 2006 Jun;12(5):459-66 [16813510.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] Integr Cancer Ther. 2003 Sep;2(3):212-6 [15035882.001]
  • [Cites] Planta Med. 2006 Mar;72(4):317-23 [16557472.001]
  • [Cites] Int J Fertil Womens Med. 2005 Nov-Dec;50(6):250-8 [16526415.001]
  • [Cites] Anal Chem. 2001 Oct 1;73(19):4704-10 [11605850.001]
  • [Cites] Cancer Causes Control. 2006 Dec;17(10):1253-61 [17111256.001]
  • [Cites] Nutr Cancer. 2006;56(1):31-9 [17176215.001]
  • [Cites] Planta Med. 2005 Jun;71(6):495-500 [15971118.001]
  • [Cites] Phytomedicine. 2005 Mar;12(3):178-82 [15830838.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Nov;97(3):271-7 [16191479.001]
  • [Cites] Expert Opin Pharmacother. 2005 Jun;6(7):1095-106 [15957964.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1523-8 [17205521.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1A):139-47 [15816531.001]
  • [Cites] Prev Med. 2005 Jul;41(1):1-6 [15916986.001]
  • (PMID = 17602247.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  • [Number-of-references] 60
  •  go-up   go-down


7. Yalniz M, Bahçecioğlu IH, Kuzu N, Celebi S, Ataseven H, Ustündağ B, Ozercan IH, Sahin K: Amelioration of steatohepatitis with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet. Dig Dis Sci; 2007 Sep;52(9):2380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum biochemistry, tumor necrosis factor-alpha (TNF-alpha), plasma, and liver tissue malondialdehyde (MDA) were analyzed.
  • Tumor growth factor-beta levels, however, were comparable in the placebo and control groups.
  • On histopathologic examination, steatosis, inflammatory cells per square millimeter, and ballooning degeneration were significantly higher in the placebo group than in the control group.
  • [MeSH-minor] Animals. Dietary Fats / toxicity. Disease Models, Animal. Disease Progression. Follow-Up Studies. Male. Organ Size. Rats. Rats, Sprague-Dawley. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2004 Oct;41(4):592-8 [15464239.001]
  • [Cites] Carcinogenesis. 2000 May;21(5):983-9 [10783322.001]
  • [Cites] Methods Enzymol. 1984;105:328-31 [6727672.001]
  • [Cites] N Engl J Med. 1997 Aug 7;337(6):396-407 [9241130.001]
  • [Cites] Cell Biochem Funct. 2004 Nov-Dec;22(6):359-63 [15386444.001]
  • [Cites] Jpn Circ J. 1981 Dec;45(12):1335-41 [7321143.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 16;288(5):1212-7 [11700041.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):679-90 [12406439.001]
  • [Cites] Hepatology. 2001 Dec;34(6):1158-63 [11732005.001]
  • [Cites] N Engl J Med. 2000 Nov 16;343(20):1467-76 [11078773.001]
  • [Cites] Am J Gastroenterol. 2002 Nov;97(11):2714-24 [12425538.001]
  • [Cites] Am J Clin Nutr. 2004 Mar;79(3):502-9 [14985228.001]
  • [Cites] Obes Rev. 2004 Feb;5(1):27-42 [14969505.001]
  • [Cites] Hepatology. 2003 May;37(5):1202-19 [12717402.001]
  • [Cites] J Clin Invest. 1994 Jan;93(1):114-20 [8282778.001]
  • [Cites] CMAJ. 2005 Mar 29;172(7):899-905 [15795412.001]
  • [Cites] Hepatology. 1990 Nov;12(5):1106-10 [2227807.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Gut. 2001 Feb;48(2):206-11 [11156641.001]
  • [Cites] Am J Pathol. 1983 Dec;113(3):309-14 [6650660.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Sep 30;155(3):1230-6 [2460096.001]
  • [Cites] Immunobiology. 1993 Apr;187(3-5):447-63 [8330908.001]
  • [Cites] Ann N Y Acad Sci. 1999 Nov 18;892:289-96 [10842669.001]
  • (PMID = 17415655.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Phosphodiesterase Inhibitors; SD6QCT3TSU / Pentoxifylline
  •  go-up   go-down


8. Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu TF, Xie WB, Yao KT: Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med; 2008;6:55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: High resistance to drug is taken as a characteristic of human tumors, which is usually mediated by multidrug resistance-associated genes.
  • In vivo, the sensitivity of the tumor tissues against cisplatin were evaluated by transplanted CNE2 nude mice model.
  • In vivo, the growth of CNE2 solid tumors with a stably transfected anti-ABCC2 siRNA construct was significantly inhibited by cisplatin in transplanted nude mice model.
  • [MeSH-major] Cisplatin / pharmacology. Lentivirus / genetics. Multidrug Resistance-Associated Proteins / deficiency. Nasopharyngeal Neoplasms / pathology. RNA Interference / drug effects. Xenograft Model Antitumor Assays
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Down-Regulation / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Humans. Intracellular Space / drug effects. Intracellular Space / metabolism. Mice. Mice, Inbred BALB C. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / metabolism

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5365-70 [11034072.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7149-58 [17145840.001]
  • [Cites] Genome Res. 2001 Jul;11(7):1156-66 [11435397.001]
  • [Cites] RNA. 2003 Apr;9(4):493-501 [12649500.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7265-79 [14576837.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5874-9 [14676109.001]
  • [Cites] J Surg Oncol. 1986 Nov;33(3):194-7 [3773537.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2434-42 [8246032.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4124-9 [8797578.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3537-47 [9270026.001]
  • [Cites] Mol Pharmacol. 1999 May;55(5):929-37 [10220572.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2157-63 [10473100.001]
  • [Cites] Acta Pharmacol Sin. 2004 Nov;25(11):1515-20 [15525476.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):393-402 [15688364.001]
  • [Cites] RNA. 2005 May;11(5):837-46 [15840823.001]
  • [Cites] J Pharmacol Toxicol Methods. 2005 Nov-Dec;52(3):366-72 [16112590.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):239-46 [16213010.001]
  • [Cites] J Pharm Biomed Anal. 2006 Mar 3;40(4):833-9 [16181764.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 15;348(1):153-7 [16876126.001]
  • [Cites] Neoplasia. 2006 Nov;8(11):917-24 [17132223.001]
  • [Cites] Cancer Gene Ther. 2007 Nov;14(11):875-84 [17704753.001]
  • [Cites] Arch Pathol Lab Med. 2008 Apr;132(4):675-83 [18384219.001]
  • [Cites] Am Fam Physician. 2001 May 1;63(9):1776-82 [11352289.001]
  • (PMID = 18834541.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / multidrug resistance-associated protein 2; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2572589
  •  go-up   go-down


9. Pietsch EC, Perchiniak E, Canutescu AA, Wang G, Dunbrack RL, Murphy ME: Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain. J Biol Chem; 2008 Jul 25;283(30):21294-304
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a model whereby positively charged residues within the H2 helix and L1 loop of p53 interact with an electronegative domain on the N-terminal alpha-helix of BAK; the latter is known to undergo conformational changes upon BAK activation.
  • We show that mutation of acidic residues in the N-terminal helix impair the ability of BAK to bind to p53.
  • The combined data point to the H2 helix and L1 and L3 loops of p53 as novel functional domains contributing to transcription-independent apoptosis by this tumor suppressor protein.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3247-57 [11714700.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9051-6 [16757565.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • [Cites] Mol Immunol. 2003 Jan;39(11):615-47 [12493639.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):577-90 [12667443.001]
  • [Cites] J Biol Chem. 2003 Jul 4;278(27):25039-45 [12721291.001]
  • [Cites] J Mol Biol. 2003 Aug 1;331(1):281-99 [12875852.001]
  • [Cites] FEBS Lett. 2004 Feb 13;559(1-3):171-4 [14960327.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]
  • [Cites] Nat Cell Biol. 2004 May;6(5):443-50 [15077116.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Cell. 1992 Nov 13;71(4):587-97 [1423616.001]
  • [Cites] Anal Biochem. 1993 Apr;210(1):179-87 [8489015.001]
  • [Cites] Cell. 1993 Sep 24;74(6):957-67 [8402885.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):1998-2002 [8134338.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3131-5 [8205530.001]
  • [Cites] Science. 1994 Jul 15;265(5170):346-55 [8023157.001]
  • [Cites] Cell. 1994 Dec 2;79(5):817-27 [8001119.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] EMBO J. 1995 Nov 15;14(22):5589-96 [8521816.001]
  • [Cites] Genes Dev. 1996 Nov 15;10(22):2859-69 [8918887.001]
  • [Cites] J Biol Chem. 1997 Sep 26;272(39):24101-4 [9305851.001]
  • [Cites] Eur J Biochem. 1997 Oct 1;249(1):85-91 [9363757.001]
  • [Cites] J Biol Chem. 1998 Oct 23;273(43):28378-83 [9774464.001]
  • [Cites] Mol Cancer Ther. 2004 Nov;3(11):1343-54 [15542773.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2108-14 [15781620.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6133-9 [16682948.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):9071-82 [17000778.001]
  • [Cites] Mol Cell. 2006 Dec 8;24(5):677-88 [17157251.001]
  • [Cites] J Biol Chem. 2007 Oct 5;282(40):29193-200 [17699158.001]
  • [Cites] Genes Dev. 2000 Aug 15;14(16):2060-71 [10950869.001]
  • [Cites] J Biol Chem. 2000 Mar 10;275(10):7337-42 [10702305.001]
  • [Cites] Science. 2000 May 12;288(5468):1053-8 [10807576.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16202-12 [10821866.001]
  • [Cites] J Biol Chem. 2000 Dec 8;275(49):38905-11 [10988287.001]
  • [Cites] Cell. 2000 Dec 8;103(6):839-42 [11136969.001]
  • [Cites] FEBS Lett. 2001 Jan 19;488(3):110-5 [11163756.001]
  • [Cites] Mol Cell. 2000 Dec;6(6):1389-99 [11163212.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Methods Cell Biol. 2001;65:1-35 [11381588.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):683-94 [11463392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41 [11517324.001]
  • [Cites] Science. 2001 Oct 19;294(5542):591-5 [11557844.001]
  • [Cites] Cell Cycle. 2005 May;4(5):637-42 [15846080.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9971-81 [16267022.001]
  • [Cites] FEBS Lett. 2005 Nov 7;579(27):6079-83 [16226255.001]
  • [Cites] Oncogene. 2006 Feb 9;25(6):940-53 [16247471.001]
  • [Cites] J Biol Chem. 2006 Mar 31;281(13):8600-6 [16443602.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):594-604 [12154352.001]
  • (PMID = 18524770.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM073784-03; United States / NCI NIH HHS / CA / T32 CA009035-33; United States / NIGMS NIH HHS / GM / R01 GM073784; United States / NCI NIH HHS / CA / CA009035-33; United States / NCI NIH HHS / CA / F32 CA110713-01; United States / NCI NIH HHS / CA / R01 CA102184-04; United States / NIGMS NIH HHS / GM / GM073784-03; United States / NCI NIH HHS / CA / P30 CA006927-44; United States / NCI NIH HHS / CA / R01 CA 102184; United States / NCI NIH HHS / CA / P30 CA 006297; United States / NCI NIH HHS / CA / F32 CA110713-02; United States / NCI NIH HHS / CA / CA102184-04; United States / NCI NIH HHS / CA / CA110713-01; United States / NCI NIH HHS / CA / R01 CA102184; United States / NCI NIH HHS / CA / CA006927-44; United States / NCI NIH HHS / CA / F32 CA 110713; United States / NCI NIH HHS / CA / T32 CA 009035; United States / NCI NIH HHS / CA / CA110713-02; United States / NIGMS NIH HHS / GM / R01 GM 73784; United States / NCI NIH HHS / CA / T32 CA009035
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAK1 protein, human; 0 / Tumor Suppressor Protein p53; 0 / bcl-2 Homologous Antagonist-Killer Protein
  • [Other-IDs] NLM/ NIHMS56188; NLM/ PMC2475706
  •  go-up   go-down


10. Cramer DW, Vitonis AF, Welch WR, Terry KL, Goodman A, Rueda BR, Berkowitz RS: Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol; 2010 Dec;119(3):462-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: CA125 at presentation of ovarian cancer carries important prognostic significance; but, other than tumor characteristics, little is known about factors that influence CA125 levels.
  • We examined the effect of epidemiologic variables and tumor features on CA125 at diagnosis and their effects on survival.
  • METHODS: CA125 levels before treatment, tumor features, and questionnaire data from 805 women with ovarian cancer receiving care at Partners Hospitals were recorded.
  • CA125 values were log-normalized and generalized linear, logistic, or Cox proportional hazards models used to identify predictors of CA125 and influence on survival in the subset of women with invasive, nonmucinous tumors.
  • CONCLUSIONS: Ovarian tumor features and presence of ascites are key determinants of CA125 at diagnosis, but epidemiologic features such as BMI, parity, prior breast cancer, and history of inflammatory conditions of the genitourinary or gastrointestinal tracts may also play a role.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Cancer. 2000 Oct 1;89(7):1555-60 [11013371.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):934-8 [7547243.001]
  • [Cites] Obstet Gynecol. 2002 Jul;100(1):59-64 [12100804.001]
  • [Cites] Int J Gynecol Cancer. 2002 Sep-Oct;12(5):438-42 [12366659.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):77-83 [12468346.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):150-4 [12620910.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Am J Med Sci. 1986 Jul;292(1):25-9 [3521278.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Mar;94(3):202-7 [3471274.001]
  • [Cites] Gynecol Oncol. 1987 Sep;28(1):61-7 [2443433.001]
  • [Cites] Gynecol Obstet Invest. 1989;27(3):143-7 [2661359.001]
  • [Cites] Obstet Gynecol. 1990 Sep;76(3 Pt 1):428-31 [2381621.001]
  • [Cites] Obstet Gynecol. 1992 Jun;79(6):1002-10 [1579296.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):87-92 [1427408.001]
  • [Cites] Gynecol Oncol. 1995 Jul;58(1):42-7 [7789889.001]
  • [Cites] J Reprod Med. 1996 Mar;41(3):140-2 [8778409.001]
  • [Cites] Genomics. 1996 Dec 15;38(3):305-13 [8975707.001]
  • [Cites] Acta Oncol. 1997;36(7):755-9 [9490096.001]
  • [Cites] Cancer. 1999 May 1;85(9):2068-72 [10223249.001]
  • [Cites] Hum Reprod Update. 1995 Mar;1(2):173-87 [15726771.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):30-5 [17220329.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):508-15 [17113137.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1383-9 [17416858.001]
  • [Cites] Biol Reprod. 2008 Jan;78(1):134-42 [17942799.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):383-9 [18586313.001]
  • [Cites] J Clin Lab Anal. 2009;23(4):244-8 [19623645.001]
  • [Cites] Int J Gynecol Cancer. 2009 Nov;19(8):1335-8 [20009886.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):489-93 [11352859.001]
  • (PMID = 20850174.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA105009-05; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / U01 CA086381-10; United States / NCI NIH HHS / CA / R01 CA54419; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / R01 CA054419; United States / NCI NIH HHS / CA / 5U01 CA86381; United States / NCI NIH HHS / CA / R01 CA054419-15
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Other-IDs] NLM/ NIHMS238531; NLM/ PMC2980911
  •  go-up   go-down


11. Goldstone SE, Enyinna CS, Davis TW: Detection of oncogenic human papillomavirus and other predictors of anal high-grade dysplasia in men who have sex with men with abnormal cytology. Dis Colon Rectum; 2009 Jan;52(1):31-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of oncogenic human papillomavirus and other predictors of anal high-grade dysplasia in men who have sex with men with abnormal cytology.
  • PURPOSE: The incidence of anal high-grade dysplasia in men who have sex with men is increasing.
  • Anal cytology that shows atypical squamous cells of undetermined significance is common, nonspecific, and rarely predicts high-grade squamous intraepithelial lesion.
  • METHODS: We performed a retrospective chart review of men who have sex with men undergoing anal screening with atypical squamous cells of undetermined significance cytology, Hybrid-Capture(R) II testing, and biopsy.
  • [MeSH-major] Anus Neoplasms / virology. Homosexuality, Male. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Precancerous Conditions / virology. Tumor Virus Infections / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Anal Canal / pathology. Anal Canal / virology. HIV Seropositivity. Humans. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273953.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Machado AL, Nomikos P, Kiesewetter F, Fahlbusch R, Buchfelder M: DNA-flow cytometry of 207 pituitary adenomas: ploidy, proliferation, and prognosis. J Endocrinol Invest; 2005 Oct;28(9):795-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DNA-flow cytometry is a useful study providing an estimation of a tumor proliferative rate.
  • The highest proliferation rates occurred in Nelson's syndrome and the lowest in Cushing's disease.
  • No single parameter revealed by DNA-flow cytometry could predict tumor prognosis or recurrence in the follow-up of 7.5 +/- 1.3 yr.
  • [MeSH-major] Adenoma / pathology. Adenoma / therapy. DNA, Neoplasm / analysis. Flow Cytometry / methods. Pituitary Neoplasms / pathology. Pituitary Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Protocols. Cell Proliferation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Ploidies. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Cell Pathol. 1998;17(2):103-10 [10052634.001]
  • [Cites] Horm Res. 1994;42(6):262-6 [7698721.001]
  • [Cites] Clin Lab Med. 2001 Dec;21(4):779-94 [11770287.001]
  • [Cites] Br J Biomed Sci. 1997 Jun;54(2):140-8 [9231461.001]
  • [Cites] Rev Med Chil. 1999 Nov;127(11):1385-97 [10835727.001]
  • [Cites] Urologe A. 1987 May;26(3):162-7 [3603902.001]
  • [Cites] Oncology. 1997 Mar-Apr;54(2):112-7 [9075781.001]
  • [Cites] Neurol India. 2001 Jun;49(2):124-7 [11447429.001]
  • [Cites] MMW Fortschr Med. 2001 Nov 1;143(44):40-2 [11732395.001]
  • [Cites] Surg Neurol. 2001 Jul;56(1):27-32 [11546567.001]
  • [Cites] J Tongji Med Univ. 1998;18(3):161-3 [10806816.001]
  • [Cites] J Neurosurg. 1986 Apr;64(4):588-93 [3950742.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Jul;43(1):79-85 [7641414.001]
  • [Cites] Int Rev Cytol. 2001;204:239-98 [11243596.001]
  • [Cites] Mol Biotechnol. 1999 Feb;11(1):37-53 [10367281.001]
  • [Cites] Methods Cell Biol. 2001;63:19-50 [11060835.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1979 Nov;42(11):973-82 [501374.001]
  • [Cites] Pituitary. 1999 Aug;2(2):117-22 [11081161.001]
  • [Cites] Clin Genet. 2001 Jul;60(1):1-8 [11531961.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:18-21 [8738487.001]
  • [Cites] Cancer. 1988 Oct 15;62(8):1556-60 [3048631.001]
  • [Cites] Cancer. 1984 Apr 15;53(8):1708-13 [6697308.001]
  • [Cites] Clin Sci (Lond). 1998 Aug;95(2):129-35 [9680493.001]
  • [Cites] Acta Neurochir (Wien). 1985;76(1-2):18-22 [2988290.001]
  • [Cites] Am J Dermatopathol. 1989 Dec;11(6):549-54 [2604022.001]
  • [Cites] J Neurosurg. 1986 Mar;64(3):402-7 [3950720.001]
  • [Cites] Curr Issues Mol Biol. 2001 Apr;3(2):37-8 [11471974.001]
  • [Cites] Clin Neurosurg. 1969;16:185-217 [5811707.001]
  • [Cites] J Neurosurg. 1986 Dec;65(6):733-44 [3095506.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):195-208 [11838791.001]
  • [Cites] J Pathol. 1992 Sep;168(1):7-13 [1360498.001]
  • [Cites] Cell Vis. 1998 Jan-Feb;5(1):56-61 [9660728.001]
  • [Cites] Am J Clin Pathol. 1981 May;75(5):734-8 [6165237.001]
  • [Cites] Radiat Environ Biophys. 1975 Jun 13;12(1):31-9 [1101288.001]
  • (PMID = 16370557.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


13. Simonaro CM, D'Angelo M, He X, Eliyahu E, Shtraizent N, Haskins ME, Schuchman EH: Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol; 2008 Jan;172(1):112-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases.
  • We have now extended these findings to synovial tissue and further explored the mechanism underlying GAG-mediated disease.
  • The expression of tumor necrosis factor, in particular, was elevated up to 50-fold, leading to up-regulation of the osteoclast survival factor, receptor activator of nuclear factor-kappaB ligand, and the appearance of multinucleated osteoclast-like cells in the MPS bone marrow.
  • These findings have important implications for the pathogenesis and treatment of MPS and have further defined the mechanism of GAG-stimulated disease.

  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • MedlinePlus Health Information. consumer health - Joint Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 2006 Jun;33(6):1061-8 [16755653.001]
  • [Cites] Pediatr Res. 2005 May;57(5 Pt 1):701-7 [15746260.001]
  • [Cites] Nat Clin Pract Rheumatol. 2005 Nov;1(1):47-54 [16932627.001]
  • [Cites] Biochem Pharmacol. 2006 Oct 30;72(9):1102-13 [16930560.001]
  • [Cites] J Inherit Metab Dis. 2006 Dec;29(6):762 [17089217.001]
  • [Cites] J Inherit Metab Dis. 2007 Feb;30(1):47-50 [17160613.001]
  • [Cites] Br J Dermatol. 2007 Mar;156(3):473-9 [17300236.001]
  • [Cites] Surg Infect (Larchmt). 2007 Feb;8(1):91-106 [17381401.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Aug;63(2):150-9 [17560117.001]
  • [Cites] Immunology. 2007 Sep;122(1):54-64 [17451462.001]
  • [Cites] QJM. 2004 Apr;97(4):205-9 [15028850.001]
  • [Cites] Curr Top Med Chem. 2004;4(11):1115-26 [15279604.001]
  • [Cites] Immunology. 2004 Oct;113(2):153-62 [15379975.001]
  • [Cites] Pediatr Res. 1975 May;9(5):475-80 [806052.001]
  • [Cites] Science. 1977 Nov 25;198(4319):834-6 [144321.001]
  • [Cites] Anal Biochem. 1982 Oct;126(1):131-8 [7181105.001]
  • [Cites] Pediatr Res. 1984 Oct;18(10):980-4 [6436780.001]
  • [Cites] J Clin Invest. 1993 Mar;91(3):1099-104 [8450039.001]
  • [Cites] Genomics. 1995 Oct 10;29(3):582-7 [8575749.001]
  • [Cites] Immunology. 1996 Dec;89(4):553-7 [9014820.001]
  • [Cites] Science. 1997 Jan 31;275(5300):628-30 [9019819.001]
  • [Cites] Transplantation. 1997 May 27;63(10):1386-93 [9175798.001]
  • [Cites] Calcif Tissue Int. 1999 Jul;65(1):47-52 [10369733.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Mar 5;269(1):70-5 [10694479.001]
  • [Cites] Arthritis Rheum. 2000 Nov;43(11):2523-30 [11083276.001]
  • [Cites] Anal Biochem. 2001 Jun 15;293(2):204-11 [11399033.001]
  • [Cites] Lab Invest. 2001 Sep;81(9):1319-28 [11555679.001]
  • [Cites] Clin Exp Immunol. 2002 Mar;127(3):547-52 [11966774.001]
  • [Cites] Curr Opin Rheumatol. 2002 Jul;14(4):406-10 [12118176.001]
  • [Cites] Clin Rheumatol. 2002 Aug;21(4):284-8 [12189454.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14362-7 [12391302.001]
  • [Cites] Acta Paediatr Suppl. 2002;91(439):88-97 [12572849.001]
  • [Cites] Arthritis Rheum. 2003 Aug;48(8):2163-72 [12905469.001]
  • [Cites] J Endotoxin Res. 2003;9(5):331-5 [14577851.001]
  • [Cites] Front Biosci. 2006;11:529-43 [16146751.001]
  • [Cites] Clin Exp Rheumatol. 2005 Sep-Oct;23(5):644-50 [16173240.001]
  • [Cites] Pediatr Res. 2006 Apr;59(4 Pt 1):538-43 [16549525.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jun 23;345(1):67-73 [16674917.001]
  • [Cites] Osteoarthritis Cartilage. 2004 Dec;12(12):963-73 [15564063.001]
  • [Cites] Curr Opin Rheumatol. 2005 Jan;17(1):70-8 [15604908.001]
  • [Cites] J Leukoc Biol. 2006 Aug;80(2):407-14 [16754725.001]
  • (PMID = 18079441.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P40 RR002512; United States / NIDDK NIH HHS / DK / R01 DK025759; United States / NIDDK NIH HHS / DK / DK 25759
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycosaminoglycans; 0 / Lipids; 0 / Lysophospholipids; 26993-30-6 / sphingosine 1-phosphate; NGZ37HRE42 / Sphingosine
  • [Other-IDs] NLM/ PMC2189614
  •  go-up   go-down


14. Donigan M, Loh BD, Norcross LS, Li S, Williamson PR, DeJesus S, Ferrara A, Gallagher JT, Baker CH: A metastatic colon cancer model using nonoperative transanal rectal injection. Surg Endosc; 2010 Mar;24(3):642-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transanal model allows for further examination of systemic immune responses, tumor take, and onset of metastasis without prior surgical intervention.
  • METHODS: For this study, 60 Balb/c mice were anesthetized and subjected to gentle anal dilation using blunt-tipped forceps at the anal opening.
  • Tumor growth and metastatic development was monitored at 5-day intervals for 50 days.
  • The overall success of tumor growth in both experiments using the transanal rectal injection was 65%.
  • Histology showed that all tumors were poorly differentiated adenocarcinomas.
  • [MeSH-major] Colonic Neoplasms / secondary. Neoplasm Transplantation / methods. Rectum / pathology
  • [MeSH-minor] Anal Canal. Animals. Cell Line, Tumor. Disease Models, Animal. Injections / methods. Mice. Mice, Inbred BALB C

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Dig Surg. 2005;22(1-2):16-25 [15838167.001]
  • [Cites] Int J Cancer. 1989 Jul 15;44(1):177-81 [2744889.001]
  • [Cites] J Surg Res. 2009 Jun 15;154(2):299-303 [19101690.001]
  • [Cites] Cancer Res. 1975 Sep;35(9):2434-9 [1149045.001]
  • [Cites] Am J Pathol. 2007 Mar;170(3):1077-85 [17322390.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1943-8 [3349467.001]
  • [Cites] Arch Surg. 1995 Jun;130(6):649-53 [7763175.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):972-8 [12640542.001]
  • [Cites] Surg Endosc. 1998 Aug;12 (8):1092-5 [9685551.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Cancer Sci. 2004 Jun;95(6):514-9 [15182433.001]
  • [Cites] Eur J Surg Oncol. 2008 Apr;34(4):476-81 [17698312.001]
  • [Cites] Surg Oncol. 1992 Jun;1(3):251-6 [1341258.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):113-20 [15942650.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2556-61 [10873112.001]
  • (PMID = 19688392.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Zheng XT, Yang HB, Li CM: Optical detection of single cell lactate release for cancer metabolic analysis. Anal Chem; 2010 Jun 15;82(12):5082-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sensitive detection of extracellular lactate concentrations at a single cell level is of importance for studying the metabolic alterations in tumor progression.
  • [MeSH-major] Biosensing Techniques / methods. Lactic Acid / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Calibration. Cell Line, Tumor. Humans. L-Lactate Dehydrogenase / metabolism. NAD / metabolism. Optical Fibers

  • Hazardous Substances Data Bank. LACTIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20469833.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0U46U6E8UK / NAD; 33X04XA5AT / Lactic Acid; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


16. Walters JD, Nakkula RJ, Maney P: Modulation of gingival fibroblast minocycline accumulation by biological mediators. J Dent Res; 2005 Apr;84(4):320-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To test this hypothesis, we treated gingival fibroblast monolayers for 1 or 6 hours with platelet-derived growth factor-BB (PDGF), fibroblast growth factor-2 (FGF), transforming growth factor-beta1 (TGF), or tumor necrosis factor-alpha (TNF).

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MINOCYCLINE .
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Periodontol. 2002 Apr;73(4):460-70 [11990448.001]
  • [Cites] Periodontol 2000. 1999 Feb;19:40-58 [10321215.001]
  • [Cites] J Periodontol. 2003 Mar;74(3):391-401 [12710761.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 10;1632(1-3):62-71 [12782152.001]
  • [Cites] Biochem Med. 1972 Jun;6(3):216-22 [5041891.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Periodontol. 1980 Sep;51(9):530-4 [6999148.001]
  • [Cites] J Clin Periodontol. 1981 Apr;8(2):117-21 [7019267.001]
  • [Cites] Anal Biochem. 1981 Aug;115(2):368-74 [7304965.001]
  • [Cites] J Clin Periodontol. 1986 Oct;13(9):841-4 [3537018.001]
  • [Cites] J Periodontol. 1987 Aug;58(8):529-39 [3305856.001]
  • [Cites] J Periodontol. 1990 Feb;61(2):103-11 [2313526.001]
  • [Cites] J Cell Physiol. 1990 May;143(2):232-42 [2159012.001]
  • [Cites] Antimicrob Agents Chemother. 1992 Dec;36(12):2634-8 [1482130.001]
  • [Cites] J Biol Chem. 1993 Mar 25;268(9):6214-20 [7681061.001]
  • [Cites] J Periodontal Res. 1993 Nov;28(6 Pt 2):500-10 [8263720.001]
  • [Cites] Periodontol 2000. 1996 Feb;10:45-78 [9567937.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 19;249(2):456-60 [9712718.001]
  • [Cites] J Dent Res. 2002 Dec;81(12):836-40 [12454098.001]
  • (PMID = 15790736.001).
  • [ISSN] 0022-0345
  • [Journal-full-title] Journal of dental research
  • [ISO-abbreviation] J. Dent. Res.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE012601; United States / NIDCR NIH HHS / DE / R01 DE012601-04; United States / NIDCR NIH HHS / DE / R01 DE012601-05; United States / NIDCR NIH HHS / DE / DE12601
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Growth Substances; EC 2.7.11.13 / Protein Kinase C; FYY3R43WGO / Minocycline; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS39574; NLM/ PMC2241671
  •  go-up   go-down


17. Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V, Lianidou ES: PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. J Mol Diagn; 2010 Sep;12(5):697-704
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The PIK3CA HRMA assay was evaluated by performing repeatability, sensitivity, and comparison with DNA sequencing studies and was further validated in 129 formalin-fixed paraffin-embedded breast tissue samples: 99 tumors, 20 noncancerous, and 10 fibroadenomas.
  • In the 99 tumor samples (validation group), 12/99 (12.1%) exon 9 mutations and 20/99 (20.2%) exon 20 mutations were found.
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. DNA Primers. Humans. Paraffin Embedding. Polymerase Chain Reaction. Reproducibility of Results. Sequence Analysis, DNA

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 May 25;19(23):2739-44 [10851074.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(2):409-18 [19418217.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):263-4 [11687795.001]
  • [Cites] Clin Chem. 2003 Jun;49(6 Pt 1):853-60 [12765979.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Clin Chem. 2004 Jul;50(7):1156-64 [15229148.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):117-27 [15324695.001]
  • [Cites] Clin Chem. 2004 Oct;50(10):1748-54 [15308590.001]
  • [Cites] J Invest Dermatol. 2004 Nov;123(5):990-2 [15482489.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Nucleic Acids Res. 1994 Jul 25;22(14):2760-8 [8052531.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):99-102 [9916799.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]
  • [Cites] Cancer Biol Ther. 2004 Aug;3(8):772-5 [15254419.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):802-7 [15647370.001]
  • [Cites] Hum Mutat. 2005 Mar;25(3):322 [15712344.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):561-73 [15950905.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R609-16 [16168105.001]
  • [Cites] Anal Biochem. 2005 Nov 1;346(1):167-75 [16188219.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):455-9 [16449998.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):608-15 [16938658.001]
  • [Cites] BMC Cancer. 2006;6:295 [17184525.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3577-84 [17575221.001]
  • [Cites] Pathol Int. 2007 Oct;57(10):664-71 [17803655.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):395-402 [17936563.001]
  • [Cites] Cancer Lett. 2008 Mar 8;261(1):120-6 [18180098.001]
  • [Cites] Clin Chem. 2008 Apr;54(4):757-60 [18375489.001]
  • [Cites] Biotechniques. 2008 Apr;44(4):577-8 [18476826.001]
  • [Cites] BMC Cancer. 2008;8:142 [18495026.001]
  • [Cites] Nucleic Acids Res. 2008 Jun;36(10):3401-8 [18448472.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):247-53 [18628094.001]
  • [Cites] Nat Med. 2008 Dec;14(12):1351-6 [19029981.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1851-7 [19223544.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1477-84 [19237633.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):725-31 [19279572.001]
  • [Cites] Ann Oncol. 2009 Jun;20(6):1020-5 [19150938.001]
  • [Cites] Med Oncol. 2009;26(3):344-9 [19016009.001]
  • [Cites] Mod Pathol. 2010 Jan;23(1):27-37 [19898424.001]
  • [Cites] Clin Biochem. 2010 Jan;43(1-2):178-85 [19747471.001]
  • [Cites] Anal Chem. 2010 Feb 15;82(4):1546-50 [20085301.001]
  • [ErratumIn] J Mol Diagn. 2013 Sep;15(5):730
  • (PMID = 20616362.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human
  • [Other-IDs] NLM/ PMC2928435
  •  go-up   go-down


18. Patriarche JW, Erickson BJ: Part 1. Automated change detection and characterization in serial MR studies of brain-tumor patients. J Digit Imaging; 2007 Sep;20(3):203-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Part 1. Automated change detection and characterization in serial MR studies of brain-tumor patients.
  • The goal of this study was to create an algorithm which would quantitatively compare serial magnetic resonance imaging studies of brain-tumor patients.
  • Automated change detection and characterization could facilitate objective review and understanding of serial magnetic resonance imaging studies in brain-tumor patients.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Mar 9;404(6774):190-3 [10724172.001]
  • [Cites] Med Image Anal. 2000 Mar;4(1):31-42 [10972319.001]
  • [Cites] Br J Radiol. 2000 Oct;73(874):1031-3 [11271893.001]
  • [Cites] Med Pediatr Oncol. 2001 Jul;37(1):1-3 [11466715.001]
  • [Cites] Br J Radiol. 2001 Nov;74(887):983-6 [11709461.001]
  • [Cites] Med Phys. 2001 Nov;28(11):2344-51 [11764042.001]
  • [Cites] Annu Rev Psychol. 2002;53:245-77 [11752486.001]
  • [Cites] Med Image Anal. 2002 Jun;6(2):163-79 [12045002.001]
  • [Cites] Neuroimage. 2003 Oct;20(2):1193-209 [14568488.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Med Phys. 1985 Sep-Oct;12(5):586-91 [4046992.001]
  • [Cites] Magn Reson Med. 1987 Jul;5(1):13-22 [3657492.001]
  • [Cites] J Comput Assist Tomogr. 1988 Jan-Feb;12(1):1-9 [3335646.001]
  • [Cites] J Comput Assist Tomogr. 1988 Mar-Apr;12(2):355-62 [3280628.001]
  • [Cites] Magn Reson Med. 1989 Jul;11(1):85-97 [2747519.001]
  • [Cites] Magn Reson Med. 1990 Apr;14(1):79-96 [2191179.001]
  • [Cites] Radiology. 1991 Jan;178(1):109-14 [1984287.001]
  • [Cites] Magn Reson Med. 1991 Mar;18(1):102-15 [2062223.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] IEEE Trans Med Imaging. 1998 Feb;17(1):74-86 [9617909.001]
  • [Cites] IEEE Trans Med Imaging. 1998 Feb;17(1):87-97 [9617910.001]
  • [Cites] Magn Reson Med. 1998 Sep;40(3):443-53 [9727948.001]
  • [Cites] J Comput Assist Tomogr. 1998 Sep-Oct;22(5):838-43 [9754126.001]
  • [Cites] Neurology. 1998 Oct;51(4):993-9 [9781519.001]
  • [Cites] IEEE Trans Med Imaging. 1999 May;18(5):429-41 [10416804.001]
  • [Cites] J Neuroimmunol. 2000 May 1;104(2):164-73 [10713356.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):179-81 [10655425.001]
  • [Cites] J Digit Imaging. 2004 Sep;17(3):158-74 [15534751.001]
  • [Cites] IEEE Trans Image Process. 2005 Mar;14(3):294-307 [15762326.001]
  • (PMID = 17216385.001).
  • [ISSN] 0897-1889
  • [Journal-full-title] Journal of digital imaging
  • [ISO-abbreviation] J Digit Imaging
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / T32 NS007494; United States / NINDS NIH HHS / NS / NS07494-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC3043896
  •  go-up   go-down


19. Ricicki EM, Luo W, Fan W, Zhao LP, Zarbl H, Vouros P: Quantification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl adducts in human lymphoblastoid TK6 cells dosed with N-hydroxy-4-acetylaminobiphenyl and their relationship to mutation, toxicity, and gene expression profiling. Anal Chem; 2006 Sep 15;78(18):6422-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl adducts in human lymphoblastoid TK6 cells dosed with N-hydroxy-4-acetylaminobiphenyl and their relationship to mutation, toxicity, and gene expression profiling.
  • A validated nano-LC microelectrospray mass spectrometry assay is reported for the detection and quantification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl (dG-C8-ABP), the principal DNA adduct of 4-aminobiphenyl.
  • [MeSH-minor] Cell Line, Tumor. Cell Survival. Chromatography, Liquid. Humans. Hypoxanthine Phosphoribosyltransferase / genetics. Thymidine Kinase / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16970317.001).
  • [ISSN] 0003-2700
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30ES07033; United States / NCI NIH HHS / CA / R01CA112231; United States / NIEHS NIH HHS / ES / U19ES011387
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminobiphenyl Compounds; 0 / DNA Adducts; 0 / Mutagens; 6810-26-0 / N-hydroxy-4-aminobiphenyl; 86408-34-6 / N-(deoxyguanosin-8-yl)-4-aminobiphenyl; EC 2.4.2.8 / Hypoxanthine Phosphoribosyltransferase; EC 2.7.1.21 / Thymidine Kinase; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


20. Brazowski E, Dotan I, Tulchinsky H, Filip I, Eisenthal A: Galectin-3 expression in pouchitis in patients with ulcerative colitis who underwent ileal pouch-anal anastomosis (IPAA). Pathol Res Pract; 2009;205(8):551-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 expression in pouchitis in patients with ulcerative colitis who underwent ileal pouch-anal anastomosis (IPAA).
  • Galectin-3, an endogenous pleiotropic beta-galactoside-binding protein, which is expressed by various malignant and normal cells, regulates many biological and pathological processes, including inflammation.
  • In the present study, we tested a possible correlation between the severity of pouchitis in patients with ulcerative colitis who underwent ileal pouch-anal anastomosis (IPAA) and the presence of galectin-3(+) macrophages in pouch mucosa.
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, Neoplasm. Biomarkers, Tumor. Female. Humans. Immunohistochemistry. Macrophages / metabolism. Macrophages / pathology. Male. Middle Aged. Prospective Studies. Young Adult


21. Giesel FL, Mehndiratta A, Locklin J, McAuliffe MJ, White S, Choyke PL, Knopp MV, Wood BJ, Haberkorn U, von Tengg-Kobligk H: Image fusion using CT, MRI and PET for treatment planning, navigation and follow up in percutaneous RFA. Exp Oncol; 2009 Jun;31(2):106-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To evaluate the feasibility of fusion of morphologic and functional imaging modalities to facilitate treatment planning, probe placement, probe re-positioning, and early detection of residual disease following radiofrequency ablation (RFA) of cancer.
  • Different combinations of imaging modalities were registered and fused prior to, during, and following percutaneous image-guided tumor ablation with radiofrequency.
  • CONCLUSION: Fusion of morphologic and functional images is feasible before, during and after radiofrequency ablation of tumors in abdominal organs.
  • [MeSH-major] Catheter Ablation. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging. Neoplasms / therapy. Positron-Emission Tomography. Therapy, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acad Radiol. 2006 Aug;13(8):986-94 [16843851.001]
  • [Cites] J Vasc Interv Radiol. 2005 Apr;16(4):493-505 [15802449.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2757-64 [18618182.001]
  • [Cites] Med Image Anal. 1998 Mar;2(1):1-36 [10638851.001]
  • [Cites] J Digit Imaging. 2000 May;13(2 Suppl 1):196-9 [10847399.001]
  • [Cites] Semin Nucl Med. 2001 Jul;31(3):191-205 [11430526.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Jun;20(6):526-34 [11437112.001]
  • [Cites] Med Image Anal. 2001 Jun;5(2):143-56 [11516708.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):443-51 [11900230.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):160-3; discussion 163 [12118750.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1129-36 [12215549.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):32-9 [12483407.001]
  • [Cites] Radiology. 2003 Feb;226(2):417-24 [12563135.001]
  • [Cites] Eur Radiol. 2003 Apr;13(4):734-9 [12664111.001]
  • [Cites] Comput Aided Surg. 2002;7(6):317-25 [12731094.001]
  • [Cites] Semin Nucl Med. 2003 Jul;33(3):205-18 [12931322.001]
  • [Cites] Med Phys. 2003 Oct;30(10):2762-92 [14596315.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):300-6 [14722039.001]
  • [Cites] J Nucl Med. 2004 Jan;45 Suppl 1:4S-14S [14736831.001]
  • [Cites] J Nucl Med. 2004 Mar;45(3):357-65 [15001674.001]
  • [Cites] Radiology. 2004 Apr;231(1):65-72 [14990824.001]
  • [Cites] Eur Radiol. 2004 May;14(5):897-901 [14666377.001]
  • [Cites] Eur J Med Res. 2004 May 28;9(5):241-6 [15257877.001]
  • [Cites] Cancer J. 2004 Jul-Aug;10(4):221-33 [15383203.001]
  • [Cites] Radiology. 1988 Dec;169(3):860-1 [3263667.001]
  • [Cites] Radiology. 1989 Sep;172(3):861-5 [2788895.001]
  • [Cites] J Nucl Med. 1990 Jul;31(7):1227-9 [2362202.001]
  • [Cites] J Nucl Med. 1993 Jul;34(7):1190-7 [8315501.001]
  • [Cites] J Nucl Med. 1993 Sep;34(9):1587-94 [8355080.001]
  • [Cites] J Nucl Med. 1994 Dec;35(12):2011-8 [7989986.001]
  • [Cites] Semin Nucl Med. 1994 Oct;24(4):256-71 [7817199.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23 Suppl):5759s-5763s [7493342.001]
  • [Cites] Nucl Med Biol. 1994 Jul;21(5):775-84 [9241654.001]
  • [Cites] Biophys Chem. 1997 Oct;68(1-3):207-19 [9468620.001]
  • [Cites] Med Image Anal. 1997 Apr;1(3):195-206 [9873906.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):883-91 [10098445.001]
  • [Cites] Am J Surg. 1999 Apr;177(4):303-6 [10326848.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2007;10(Pt 2):969-77 [18044662.001]
  • (PMID = 19550401.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010714-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Ukraine
  • [Other-IDs] NLM/ NIHMS188708; NLM/ PMC2850071
  •  go-up   go-down


22. Rui Q, Komori K, Tian Y, Liu H, Luo Y, Sakai Y: Electrochemical biosensor for the detection of H2O2 from living cancer cells based on ZnO nanosheets. Anal Chim Acta; 2010 Jun 18;670(1-2):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biosensing Techniques. Cytochromes c / metabolism. Hydrogen Peroxide / analysis. Liver Neoplasms / metabolism. Nanotubes / chemistry. Zinc Oxide / chemistry
  • [MeSH-minor] Adsorption. Animals. Biocatalysis. Cell Line, Tumor. Electrochemistry. Electron Transport. Horses. Humans. Oxidation-Reduction. Particle Size. Surface Properties

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ZINC OXIDE .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20685417.001).
  • [ISSN] 1873-4324
  • [Journal-full-title] Analytica chimica acta
  • [ISO-abbreviation] Anal. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 9007-43-6 / Cytochromes c; BBX060AN9V / Hydrogen Peroxide; SOI2LOH54Z / Zinc Oxide
  •  go-up   go-down


23. Dill AL, Ifa DR, Manicke NE, Ouyang Z, Cooks RG: Mass spectrometric imaging of lipids using desorption electrospray ionization. J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Sep 15;877(26):2883-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipids play important biological roles and differences in lipid compositions have been seen in diseases such as cancer and Alzheimer's disease.
  • DESI-MS has been used to image a variety of tissue samples including human liver adenocarcinoma, rat brain, human breast tissue and canine abdominal tumor tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Mass Spectrom. 2008 Apr;19(4):531-43 [18258448.001]
  • [Cites] Nat Protoc. 2008;3(3):517-24 [18323820.001]
  • [Cites] Anal Chem. 2008 Jun 15;80(12):4575-82 [18473485.001]
  • [Cites] Anal Chem. 2008 Jul 1;80(13):5168-77 [18481874.001]
  • [Cites] Science. 2008 Aug 8;321(5890):805 [18687956.001]
  • [Cites] Rapid Commun Mass Spectrom. 2008 Sep;22(17):2639-44 [18666197.001]
  • [Cites] Anal Chem. 2008 Nov 1;80(21):7921-9 [18844371.001]
  • [Cites] Anal Chem. 2008 Dec 1;80(23):8865-70 [19040400.001]
  • [Cites] Anal Chem. 2000 Feb 15;72(4):652-7 [10701247.001]
  • [Cites] Anal Chem. 2000 Nov 1;72(21):5239-43 [11080870.001]
  • [Cites] Nat Med. 2001 Apr;7(4):493-6 [11283679.001]
  • [Cites] J Mass Spectrom. 2001 Apr;36(4):355-69 [11333438.001]
  • [Cites] Free Radic Biol Med. 2002 Sep 1;33(5):620-6 [12208348.001]
  • [Cites] Indian J Exp Biol. 2002 Jun;40(6):656-67 [12587714.001]
  • [Cites] J Mass Spectrom. 2003 Jul;38(7):699-708 [12898649.001]
  • [Cites] Anal Chem. 2003 Jul 15;75(14):3429-34 [14570193.001]
  • [Cites] Anal Chem. 2004 Mar 15;76(6):1550-9 [15018551.001]
  • [Cites] Anal Chem. 2004 Mar 15;76(6):1657-63 [15018564.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4270-6 [15205341.001]
  • [Cites] Science. 2004 Jul 2;305(5680):71-3 [15232100.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):3930-4 [15253626.001]
  • [Cites] Anal Chem. 2004 Aug 1;76(15):4271-8 [15283560.001]
  • [Cites] J Card Fail. 2004 Aug;10(4):334-8 [15309701.001]
  • [Cites] J Am Soc Mass Spectrom. 2004 Oct;15(10):1499-508 [15465363.001]
  • [Cites] J Lipid Res. 1983 Apr;24(4):456-60 [6854152.001]
  • [Cites] J Lipid Res. 1984 Jul;25(7):738-49 [6481246.001]
  • [Cites] Lipids. 1987 Jul;22(7):480-9 [3626775.001]
  • [Cites] J Lipid Res. 1994 Jun;35(6):1102-14 [8077849.001]
  • [Cites] Anal Chem. 1994 Nov 15;66(22):3977-82 [7810900.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2028-34 [9329967.001]
  • [Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):80-4 [9892190.001]
  • [Cites] Anal Biochem. 1999 Feb 1;267(1):46-56 [9918654.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):279-86 [15591226.001]
  • [Cites] J Mass Spectrom. 2005 Aug;40(8):985-99 [16106340.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Nov 4;44(43):7094-7 [16259018.001]
  • [Cites] Analyst. 2005 Dec;130(12):1624-33 [16284661.001]
  • [Cites] J Chromatogr A. 2006 Mar 31;1110(1-2):86-94 [16480731.001]
  • [Cites] Chem Commun (Camb). 2006 Apr 28;(16):1709-11 [16609779.001]
  • [Cites] J Proteome Res. 2006 May;5(5):1107-16 [16674100.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(10):1577-84 [16628593.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(18):2717-27 [16912984.001]
  • [Cites] J Lipid Res. 2006 Oct;47(10):2101-11 [16902246.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(22):3403-8 [17051609.001]
  • [Cites] Angew Chem Int Ed Engl. 2006 Nov 6;45(43):7188-92 [17001721.001]
  • [Cites] Anal Bioanal Chem. 2007 Jan;387(2):539-49 [16821030.001]
  • [Cites] Anal Chem. 2007 Mar 15;79(6):2199-206 [17302385.001]
  • [Cites] Anal Chem. 2007 May 1;79(9):3514-8 [17394289.001]
  • [Cites] Analyst. 2007 May;132(5):461-7 [17471393.001]
  • [Cites] Anal Chem. 2007 Nov 1;79(21):8098-106 [17900146.001]
  • [Cites] Anal Chem. 2008 Apr 15;80(8):2780-8 [18314967.001]
  • (PMID = 19150258.001).
  • [ISSN] 1873-376X
  • [Journal-full-title] Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • [ISO-abbreviation] J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM058008-07; United States / NIGMS NIH HHS / GM / R01 GM058008; United States / NIGMS NIH HHS / GM / 5R01 GM58008-07; United States / NIGMS NIH HHS / GM / R01 GM058008-07
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Lipids
  • [Other-IDs] NLM/ NIHMS227068; NLM/ PMC2921711
  •  go-up   go-down


24. Sunil VR, Patel KJ, Mainelis G, Turpin BJ, Ridgely S, Laumbach RJ, Kipen HM, Nazarenko Y, Veleeparambil M, Gow AJ, Laskin JD, Laskin DL: Pulmonary effects of inhaled diesel exhaust in aged mice. Toxicol Appl Pharmacol; 2009 Dec 15;241(3):283-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present studies analyzed potential mechanisms underlying increased susceptibility of the elderly to PM using diesel exhaust (DE) as a model.
  • Mice (2 m and 18 m) were exposed to DE (0, 300, and 1000 microg/m(3)) for 3 h once (single) or 3 h/day for 3 days (repeated).
  • Exposure to DE resulted in structural alterations in the lungs of older but not younger mice, including patchy thickening of the alveolar septa and inflammatory cell localization in alveolar spaces.
  • These effects were most pronounced 24 h after a single exposure to the higher dose of DE.
  • Following DE inhalation, expression of Tumor Necrosis Factor alpha (TNFalpha) was upregulated in lungs of both younger and older mice; however, this was attenuated in older animals.
  • Whereas exposure to DE resulted in increases in lung Interleukin-6 (IL-6) expression in both older and younger mice, IL-8 increased only in older animals.
  • In younger mice, constitutive expression of manganese superoxide dismutase (MnSOD) decreased after DE exposure, while in older mice, constitutive MnSOD was not detectable and DE had no effect on expression of this antioxidant.
  • Taken together, these results suggest that altered generation of inflammatory mediators and MnSOD may contribute to increased susceptibility of older mice to inhaled DE.

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1999 Nov 15;163(10):5582-91 [10553087.001]
  • [Cites] Mediators Inflamm. 2000;9(3-4):155-60 [11132772.001]
  • [Cites] Mech Ageing Dev. 2000 Dec 20;121(1-3):89-100 [11164463.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2622-7 [11226289.001]
  • [Cites] J Infect Dis. 2001 Mar 15;183(6):943-52 [11237812.001]
  • [Cites] Res Rep Health Eff Inst. 2000 Jun;94(Pt 2):5-70; discussion 71-9 [11354823.001]
  • [Cites] Eur Respir J. 2001 Apr;17(4):733-46 [11401072.001]
  • [Cites] Exp Gerontol. 2001 Sep;36(9):1539-50 [11525876.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L755-65 [12225952.001]
  • [Cites] Antioxid Redox Signal. 2002 Aug;4(4):587-92 [12230870.001]
  • [Cites] J Immunol. 2002 Oct 15;169(8):4531-41 [12370390.001]
  • [Cites] Environ Health Perspect. 2002 Nov;110(11):1105-11 [12417481.001]
  • [Cites] Chest. 2002 Dec;122(6 Suppl):314S-320S [12475808.001]
  • [Cites] Exp Gerontol. 2002 Dec;37(12):1325-31 [12559402.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Apr 4;303(2):483-7 [12659843.001]
  • [Cites] Eur Respir J Suppl. 2003 May;40:70s-75s [12762578.001]
  • [Cites] Aging Cell. 2003 Jun;2(3):159-64 [12882408.001]
  • [Cites] J Appl Physiol (1985). 2003 Oct;95(4):1681-7 [12794030.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Dec 1;193(2):218-27 [14644624.001]
  • [Cites] J Leukoc Biol. 2004 Feb;75(2):342-9 [14634059.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Mar;30(3):280-7 [12855403.001]
  • [Cites] Mech Ageing Dev. 2004 Feb;125(2):145-6 [15037020.001]
  • [Cites] Z Gerontol Geriatr. 2004 Apr;37(2):109-35 [15103481.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):100-12 [15305381.001]
  • [Cites] J Immunol. 2004 Sep 1;173(5):3467-81 [15322212.001]
  • [Cites] Infect Immun. 2004 Oct;72(10):6002-11 [15385504.001]
  • [Cites] Int J Environ Anal Chem. 1981;9(2):93-144 [7012053.001]
  • [Cites] Am Rev Respir Dis. 1990 Mar;141(3):765-88 [2155556.001]
  • [Cites] Mech Ageing Dev. 1990 Mar 1;52(1):11-26 [2314126.001]
  • [Cites] Environ Res. 1992 Dec;59(2):362-73 [1464289.001]
  • [Cites] Free Radic Biol Med. 1993 Jan;14(1):37-47 [8384149.001]
  • [Cites] J Biol Chem. 1995 Sep 22;270(38):22565-70 [7545679.001]
  • [Cites] Gut. 1996 Mar;38(3):414-20 [8675096.001]
  • [Cites] Vet Immunol Immunopathol. 1996 Nov;54(1-4):45-55 [8988847.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(2):101-4 [9065665.001]
  • [Cites] Exp Lung Res. 1998 Jan-Feb;24(1):85-100 [9457471.001]
  • [Cites] Methods Enzymol. 1999;299:83-8 [9916199.001]
  • [Cites] Ann Occup Hyg. 1999 Jan;43(1):7-33 [10028891.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Mar;159(3):702-9 [10051240.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1999 Jan-Mar;2(1):31-86 [10081525.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Nov;229(10):1081-7 [15522845.001]
  • [Cites] Bone. 2005 Feb;36(2):300-10 [15780956.001]
  • [Cites] Free Radic Res. 2005 Mar;39(3):305-16 [15788235.001]
  • [Cites] Eur Respir J. 2005 Oct;26(4):563-5 [16204583.001]
  • [Cites] Eur J Pharmacol. 2006 Mar 8;533(1-3):240-52 [16464450.001]
  • [Cites] Pediatr Nephrol. 2006 Jun;21(6):856-63 [16528543.001]
  • [Cites] Exp Lung Res. 2006 Oct;32(9):427-39 [17162650.001]
  • [Cites] Brain Behav Immun. 2007 Mar;21(3):281-9 [17275255.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Jul 15;222(2):211-20 [17610924.001]
  • [Cites] Inhal Toxicol. 2007 Aug;19(10):811-32 [17687714.001]
  • [Cites] J Gen Virol. 2007 Sep;88(Pt 9):2552-8 [17698666.001]
  • [Cites] Exp Mol Pathol. 2007 Oct;83(2):177-87 [17490638.001]
  • [Cites] Exp Lung Res. 2007 Sep;33(7):375-84 [17849263.001]
  • [Cites] Expert Opin Biol Ther. 2008 May;8(5):657-68 [18407768.001]
  • [Cites] Expert Rev Vaccines. 2008 May;7(4):467-79 [18444893.001]
  • [Cites] Clin Exp Immunol. 2008 Jun;152(3):448-55 [18422728.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Jun 15;229(3):310-9 [18343473.001]
  • [Cites] Crit Care. 2008;12(2):R41 [18358078.001]
  • [Cites] FEMS Immunol Med Microbiol. 2008 Jul;53(2):214-21 [18445021.001]
  • [Cites] Georgian Med News. 2008 Jun;(159):47-52 [18633152.001]
  • [Cites] J Radiat Res. 2007 Jan;48(1):39-44 [17229997.001]
  • (PMID = 19729031.001).
  • [ISSN] 1096-0333
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA132624; United States / NIEHS NIH HHS / ES / K08 ES013520-04; United States / NIEHS NIH HHS / ES / ES005022-21; United States / NIAMS NIH HHS / AR / U54 AR055073-04; United States / NIGMS NIH HHS / GM / GM034310-23; United States / NCI NIH HHS / CA / CA132624; United States / NHLBI NIH HHS / HL / R01 HL086621; United States / NIEHS NIH HHS / ES / R01 ES004738-14; United States / NIAMS NIH HHS / AR / U54 AR055073-02; United States / NCI NIH HHS / CA / CA132624-02; United States / NIEHS NIH HHS / ES / R01 ES004738-10; United States / NIAMS NIH HHS / AR / AR055073; United States / NIEHS NIH HHS / ES / ES013520-04; United States / NIAMS NIH HHS / AR / AR055073-04; United States / NIEHS NIH HHS / ES / ES004738-10; United States / NIEHS NIH HHS / ES / K08 ES013520-03; United States / NIEHS NIH HHS / ES / P30 ES005022; United States / NIEHS NIH HHS / ES / P30 ES005022-20; United States / NIAMS NIH HHS / AR / U54 AR055073-01; United States / NIAMS NIH HHS / AR / AR055073-01; United States / NIEHS NIH HHS / ES / ES004738-14; United States / NIAMS NIH HHS / AR / AR055073-02; United States / NIEHS NIH HHS / ES / ES013520; United States / NIGMS NIH HHS / GM / R01 GM034310; United States / NCI NIH HHS / CA / CA132624-01; United States / NIAMS NIH HHS / AR / U54 AR055073; United States / NIGMS NIH HHS / GM / R01 GM034310-23; United States / NIEHS NIH HHS / ES / ES013520-02; United States / NIEHS NIH HHS / ES / P30 ES005022-21; United States / NIEHS NIH HHS / ES / K08 ES013520-02; United States / NIEHS NIH HHS / ES / R01 ES004738-15; United States / NIEHS NIH HHS / ES / ES005022; United States / NIAMS NIH HHS / AR / AR055073-03; United States / NIGMS NIH HHS / GM / GM034310; United States / NCI NIH HHS / CA / R01 CA132624-01; United States / NIGMS NIH HHS / GM / R01 GM034310-24; United States / NIEHS NIH HHS / ES / ES004738-15; United States / NIEHS NIH HHS / ES / ES004738; United States / NIEHS NIH HHS / ES / K08 ES013520; United States / NCI NIH HHS / CA / R01 CA132624-02; United States / NIGMS NIH HHS / GM / GM034310-24; United States / NIEHS NIH HHS / ES / ES013520-03; United States / NIAMS NIH HHS / AR / U54 AR055073-03; United States / NIEHS NIH HHS / ES / R01 ES004738
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Antioxidants; 0 / Inflammation Mediators; 0 / Nitrogen Oxides; 0 / Particulate Matter; 0 / Tumor Necrosis Factor-alpha; 0 / Vehicle Emissions; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ NIHMS210916; NLM/ PMC3102559
  •  go-up   go-down


25. Chen EI, Yates JR 3rd: Cancer proteomics by quantitative shotgun proteomics. Mol Oncol; 2007 Sep;1(2):144-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Understanding the molecular basis of cancer requires studying the dynamic and spatial interactions among proteins in cells, signaling events among cancer cells, and interactions between the cancer cells and the tumor microenvironment.
  • Advances in mass spectrometry technologies and bioinformatics tools provide a tremendous opportunity to qualitatively and quantitatively interrogate dynamic protein-protein interactions and differential regulation of cellular signaling pathways associated with tumor development.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Neoplasm Proteins / biosynthesis. Neoplasms / metabolism. Proteome / biosynthesis. Proteomics / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14694-9 [10611275.001]
  • [Cites] J Exp Bot. 2006;57(7):1501-8 [16574745.001]
  • [Cites] Brief Funct Genomic Proteomic. 2006 Jun;5(2):112-20 [16772272.001]
  • [Cites] Anal Chem. 2002 Apr 1;74(7):1650-7 [12043600.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):801-8 [15952726.001]
  • [Cites] J Proteome Res. 2005 Sep-Oct;4(5):1661-71 [16212419.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):26021-30 [12714601.001]
  • [Cites] Rapid Commun Mass Spectrom. 2002;16(22):2115-23 [12415544.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):94-101 [15592455.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):621-6 [15253445.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):45662-8 [15326169.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6021-5 [12414622.001]
  • [Cites] Curr Opin Chem Biol. 2005 Oct;9(5):424-30 [16129650.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12 (2):192-8 [16482617.001]
  • [Cites] Proteomics. 2004 Apr;4(4):1116-34 [15048993.001]
  • [Cites] Mol Cell Proteomics. 2007 Mar;6(3):479-91 [17151021.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6591-6 [10359756.001]
  • [Cites] J Proteome Res. 2006 Oct;5(10):2743-53 [17022645.001]
  • [Cites] Annu Rev Immunol. 2000;18:621-63 [10837071.001]
  • [Cites] Anal Chem. 2003 Dec 15;75(24):6912-21 [14670053.001]
  • [Cites] Proteome Sci. 2007 Jan 15;5:2 [17224053.001]
  • [Cites] Anal Chem. 2002 Oct 1;74(19):4969-79 [12380819.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] J Chromatogr A. 2004 Oct 8;1051(1-2):3-17 [15532550.001]
  • [Cites] Nat Methods. 2004 Dec;1(3):195-202 [15789030.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1408-16 [9537241.001]
  • [Cites] Anal Chem. 2004 May 15;76(10):2763-72 [15144186.001]
  • [Cites] J Proteome Res. 2005 Mar-Apr;4(2):377-86 [15822913.001]
  • [Cites] Proteomics. 2004 Sep;4(9):2594-601 [15352234.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2193-8 [17287358.001]
  • [Cites] Proteomics. 2006 Jul;6(13):3871-9 [16739137.001]
  • [Cites] Cell. 2006 Nov 3;127(3):635-48 [17081983.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1138-42 [16083264.001]
  • [Cites] Anal Chem. 2006 Jul 15;78(14):5109-18 [16841936.001]
  • [Cites] Proteomics. 2004 Dec;4(12):3665-85 [15543535.001]
  • [Cites] Curr Opin Biotechnol. 2003 Feb;14(1):101-9 [12566009.001]
  • [Cites] Nature. 2002 Oct 3;419(6906):520-6 [12368866.001]
  • [Cites] Anal Chem. 2006 Aug 15;78(16):5752-61 [16906720.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Aug;3(8):448-57 [16894390.001]
  • [Cites] Pancreas. 2005 Oct;31(3):258-62 [16163058.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1774-9 [11842225.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):369-76 [12923544.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10 ):793-805 [15510160.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6657-66 [16091754.001]
  • [Cites] J Proteome Res. 2003 Jul-Aug;2(4):373-82 [12938927.001]
  • [Cites] J Proteome Res. 2003 Nov-Dec;2(6):643-9 [14692458.001]
  • [Cites] J Biol Chem. 1997 Oct 24;272(43):26799-802 [9341106.001]
  • [Cites] Anal Chem. 2006 Dec 15;78(24):8207-17 [17165809.001]
  • [Cites] Mol Cell Proteomics. 2006 Nov;5(11):2167-74 [16854842.001]
  • [Cites] J Exp Bot. 2006;57(7):1529-35 [16574747.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):640-6 [9818175.001]
  • [Cites] J Proteome Res. 2006 Feb;5(2):233-9 [16457587.001]
  • [Cites] J Biochem. 2004 Jul;136(1):97-106 [15269245.001]
  • [Cites] Methods Mol Biol. 2004;261:511-8 [15064479.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(8):869-76 [15095355.001]
  • [Cites] Mol Cell Proteomics. 2006 Jan;5(1):157-71 [16215274.001]
  • [Cites] Anal Chem. 2002 Sep 1;74(17):4353-60 [12236342.001]
  • [Cites] Cell. 1991 Jan 25;64(2):281-302 [1846320.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] Anal Chem. 2006 Jul 1;78(13):4271-80 [16808433.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6316-25 [14695130.001]
  • [Cites] Biotechniques. 2002 Apr;32(4):898, 900, 902 passim [11962611.001]
  • [Cites] Anal Chem. 2003 Dec 1;75(23):6648-57 [14640741.001]
  • [Cites] Electrophoresis. 2005 Jan;26(1):248-56 [15624161.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1265-72 [15958392.001]
  • [Cites] Anal Chem. 2001 May 1;73(9):2132-9 [11354501.001]
  • [Cites] J Proteome Res. 2003 Jan-Feb;2(1):43-50 [12643542.001]
  • [Cites] Science. 1995 Apr 28;268(5210):522-3 [7725095.001]
  • [Cites] J Proteome Res. 2006 Feb;5(2):240-7 [16457588.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):433-43 [16319398.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5859-65 [14522910.001]
  • [Cites] Anal Chem. 2003 May 15;75(10):2355-61 [12918977.001]
  • [Cites] Genome Biol. 2005;6(10):233 [16207362.001]
  • [Cites] J Biol Chem. 1995 Jun 30;270(26):15832-7 [7797587.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1727-44 [16887931.001]
  • [Cites] Electrophoresis. 1993 May-Jun;14(5-6):439-47 [8354227.001]
  • [Cites] Oral Oncol. 2005 Feb;41(2):183-99 [15695121.001]
  • [Cites] Anal Chem. 1997 Jul 1;69(13):2283-91 [9212702.001]
  • [Cites] EMBO J. 1997 Sep 15;16(18):5509-19 [9312010.001]
  • [Cites] J Proteome Res. 2006 May;5(5):1143-54 [16674103.001]
  • [Cites] Anal Biochem. 2001 Oct 1;297(1):25-31 [11567524.001]
  • [Cites] BMC Cancer. 2006 Mar 16;6:68 [16542425.001]
  • [Cites] Nat Biotechnol. 2006 Oct;24(10):1285-92 [16964243.001]
  • [Cites] Anal Chem. 2006 Feb 1;78(3):686-94 [16448040.001]
  • [Cites] J Endotoxin Res. 2005;11(6):325-32 [16303087.001]
  • [Cites] J Am Soc Mass Spectrom. 2002 Jun;13(6):659-69 [12056566.001]
  • [Cites] Proteomics. 2003 Apr;3(4):422-32 [12687610.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6218-24 [16194081.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]
  • [Cites] Curr Opin Chem Biol. 2006 Feb;10(1):42-9 [16418010.001]
  • [Cites] Anal Bioanal Chem. 2005 Jun;382(3):669-78 [15900442.001]
  • [Cites] Anal Chem. 2004 Sep 1;76(17):4951-9 [15373428.001]
  • [Cites] Nat Med. 2000 Feb;6(2):196-9 [10655109.001]
  • [Cites] Anal Chem. 2006 Jan 15;78(2):493-500 [16408932.001]
  • [Cites] Proteomics. 2005 Jul;5(11):2748-60 [15952233.001]
  • [Cites] Clin Chem Lab Med. 2003 Dec;41(12):1562-70 [14708880.001]
  • [Cites] Jpn Circ J. 1995 Jan;59(1):40-8 [7752444.001]
  • [Cites] Curr Opin Cell Biol. 1997 Dec;9(6):788-99 [9425343.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2795-800 [12591958.001]
  • [Cites] Biomed Mass Spectrom. 1983 Aug;10(8):471-9 [6616023.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4104-11 [15253649.001]
  • [Cites] Science. 2007 Jan 12;315(5809):201-5 [17218518.001]
  • [Cites] Anal Biochem. 1993 Nov 1;214(2):397-408 [8109726.001]
  • [Cites] Nat Methods. 2004 Oct;1(1):39-45 [15782151.001]
  • [Cites] Mol Cell Proteomics. 2003 May;2(5):281-91 [12775769.001]
  • [Cites] Mol Cell Proteomics. 2006 Sep;5(9):1593-609 [16835217.001]
  • [Cites] Cellscience. 2006 Jul 27;3(1):61-81 [17205105.001]
  • [Cites] Cell Cycle. 2005 Jul;4(7):908-13 [15917664.001]
  • [Cites] Rapid Commun Mass Spectrom. 2003;17(10):1056-64 [12720286.001]
  • [Cites] Anal Chem. 2000 Mar 15;72(6):1099-111 [10740846.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):443-8 [12522270.001]
  • [Cites] J Proteome Res. 2002 Jan-Feb;1(1):21-6 [12643522.001]
  • [Cites] Electrophoresis. 1997 Oct;18(11):2071-7 [9420172.001]
  • [Cites] Anal Chem. 2006 Sep 15;78(18):6448-56 [16970320.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • [Cites] Nat Biotechnol. 2001 Mar;19(3):242-7 [11231557.001]
  • [Cites] Anal Chem. 2001 Dec 1;73(23):5683-90 [11774908.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1652-9 [8939846.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] Nat Biotechnol. 2005 May;23(5):617-21 [15834404.001]
  • [Cites] Science. 2006 Apr 14;312(5771):212-7 [16614208.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):419-34 [15741312.001]
  • [Cites] Mol Cell Proteomics. 2004 Jul;3(7):729-35 [15102926.001]
  • [Cites] Anal Chem. 2004 Jul 1;76(13):3556-68 [15228325.001]
  • [Cites] J Mass Spectrom. 2007 Mar;42(3):312-34 [17206599.001]
  • [Cites] Anal Chem. 1999 Dec 1;71(23):5263-70 [10596208.001]
  • [Cites] J Proteome Res. 2002 Mar-Apr;1(2):161-9 [12643536.001]
  • [Cites] J Cell Biol. 1982 Mar;92 (3):822-32 [6282895.001]
  • [Cites] J Proteome Res. 2003 Mar-Apr;2(2):173-81 [12716131.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6940-5 [12771378.001]
  • [Cites] Mol Cell Proteomics. 2006 Apr;5(4):714-25 [16401633.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5578-87 [15994930.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Nat Biotechnol. 2001 Apr;19(4):379-82 [11283599.001]
  • [Cites] Anal Chem. 2007 May 15;79(10):3623-34 [17411013.001]
  • [Cites] Clin Chem. 1996 Oct;42(10):1676-82 [8855153.001]
  • [Cites] Bioconjug Chem. 2004 Mar-Apr;15(2):380-8 [15025535.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):604-12 [15253443.001]
  • [Cites] Nat Med. 2000 Apr;6(4):374-6 [10742136.001]
  • [Cites] Mass Spectrom Rev. 2003 Jul-Aug;22(4):272-84 [12884390.001]
  • [Cites] World J Gastroenterol. 2006 Nov 7;12(41):6594-601 [17075970.001]
  • [Cites] J Proteome Res. 2006 Sep;5(9):2328-38 [16944945.001]
  • [Cites] J Proteome Res. 2006 Mar;5(3):695-700 [16512685.001]
  • [Cites] Nat Biotechnol. 2003 Aug;21(8):921-6 [12872131.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11669-74 [8876194.001]
  • [Cites] Breast Cancer Res Treat. 1987;9(2):111-21 [3620713.001]
  • [Cites] J Proteome Res. 2006 Nov;5(11):2889-900 [17081040.001]
  • [Cites] Cell Death Differ. 1999 Apr;6(4):303-13 [10381632.001]
  • [Cites] J Proteome Res. 2002 Jul-Aug;1(4):351-60 [12645891.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1764(12):1811-22 [17118725.001]
  • [Cites] Nat Biotechnol. 2004 Apr;22(4):450-4 [15004565.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]
  • [Cites] J Am Soc Mass Spectrom. 1994 Nov;5(11):976-89 [24226387.001]
  • [Cites] FASEB J. 2005 Jul;19(9):1123-4 [15857880.001]
  • [Cites] Anal Chem. 2006 Oct 15;78(20):7121-31 [17037911.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8 [11597398.001]
  • [Cites] J Am Soc Mass Spectrom. 2002 Nov;13(11):1292-7 [12443019.001]
  • [Cites] J Biochem Mol Biol. 2004 Jan 31;37(1):35-44 [14761301.001]
  • [Cites] Mol Oncol. 2007 Sep;1(2):144-59 [18443658.001]
  • [Cites] Mol Cell Proteomics. 2006 Apr;5(4):573-88 [16332733.001]
  • [Cites] Methods. 2006 Dec;40(4):303-11 [17101441.001]
  • [Cites] Curr Opin Genet Dev. 2003 Apr;13(2):108-13 [12672486.001]
  • [Cites] Drug Discov Today. 2004 Feb 15;9(4):173-81 [14960397.001]
  • [Cites] Ann N Y Acad Sci. 2007 Mar;1098:323-9 [17435138.001]
  • (PMID = 18443658.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH067880; United States / NIMH NIH HHS / MH / R01 MH067880-05; United States / NIMH NIH HHS / MH / 5R01MH067880-02; United States / PHS HHS / / UCSD/MCB0237059; United States / NCRR NIH HHS / RR / P41 RR011823; United States / NCRR NIH HHS / RR / P41 RR11823-10; United States / NCRR NIH HHS / RR / P41 RR011823-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proteome
  • [Number-of-references] 166
  • [Keywords] NOTNLM ; cancer cells / mass spectrometry / protein profiling / quantitative proteomics / shotgun proteomics
  •  go-up   go-down


26. Coppola JM, Bhojani MS, Ross BD, Rehemtulla A: A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia; 2008 Apr;10(4):363-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additionally, the expression and activity of furin/PC are necessary for processing substrates important for cell transformation and tumor progression, metastasis, and angiogenesis.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2007 Apr;27(8):2997-3007 [17283058.001]
  • [Cites] Anal Biochem. 2007 May 1;364(1):19-29 [17316541.001]
  • [Cites] Lab Invest. 2002 Dec;82(12):1673-84 [12480917.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1458-63 [12670890.001]
  • [Cites] Cancer Lett. 2003 May 8;194(1):1-11 [12706853.001]
  • [Cites] J Clin Invest. 2003 Jun;111(11):1723-32 [12782675.001]
  • [Cites] FASEB J. 2003 Jul;17(10):1215-27 [12832286.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):569-74 [12841863.001]
  • [Cites] Exp Cell Res. 2003 Dec 10;291(2):326-39 [14644155.001]
  • [Cites] J Neurosci. 2004 Jun 16;24(24):5482-91 [15201320.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10560-5 [15247425.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36219-27 [15140896.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36788-94 [15197180.001]
  • [Cites] J Clin Invest. 1987 Dec;80(6):1545-9 [2824565.001]
  • [Cites] Blood. 1992 May 1;79(9):2349-55 [1571548.001]
  • [Cites] Infect Immun. 1994 Feb;62(2):333-40 [8300195.001]
  • [Cites] Infect Immun. 1995 Jan;63(1):82-7 [7806387.001]
  • [Cites] J Biol Chem. 1995 Jan 13;270(2):801-5 [7822314.001]
  • [Cites] FEBS Lett. 1996 Sep 9;393(1):101-4 [8804434.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):30174-80 [8939968.001]
  • [Cites] J Clin Invest. 1997 Apr 15;99(8):1974-83 [9109442.001]
  • [Cites] Int J Cancer. 1997 Jun 11;71(6):966-71 [9185698.001]
  • [Cites] FEBS Lett. 1998 Mar 13;424(3):262-6 [9539163.001]
  • [Cites] Biochem J. 1997 Nov 1;327 ( Pt 3):625-35 [9599222.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7293-8 [9636142.001]
  • [Cites] Biochem J. 1999 Feb 15;338 ( Pt 1):107-13 [9931305.001]
  • [Cites] Trends Cell Biol. 1999 Jan;9(1):28-35 [10087614.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] J Cell Sci. 2004 Dec 15;117(Pt 26):6275-87 [15561768.001]
  • [Cites] Mol Carcinog. 2005 Nov;44(3):151-61 [16167351.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6925-35 [16007151.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19707-12 [17179036.001]
  • [Cites] FASEB J. 2007 Apr;21(4):1088-98 [17242158.001]
  • [Cites] Cell Oncol. 2007;29(4):289-99 [17641413.001]
  • [Cites] Mol Carcinog. 2007 Aug;46(8):654-9 [17440928.001]
  • [Cites] Mol Biol Cell. 2000 Jul;11(7):2387-401 [10888676.001]
  • [Cites] Mol Carcinog. 2000 Jun;28(2):63-9 [10900462.001]
  • [Cites] Biochim Biophys Acta. 2000 Nov 10;1469(3):121-32 [11063880.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36741-9 [10958789.001]
  • [Cites] Biochem J. 2001 Feb 1;353(Pt 3):537-45 [11171050.001]
  • [Cites] Cell Microbiol. 2000 Jun;2(3):251-8 [11207581.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6642-50 [11426650.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):30686-93 [11402025.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10326-31 [11517338.001]
  • [Cites] Mol Carcinog. 2001 Aug;31(4):224-32 [11536372.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1921-35 [12057895.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1740-6 [12060611.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):30271-82 [12058032.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Oct;3(10):753-66 [12360192.001]
  • [Cites] Chem Rev. 2002 Dec;102(12):4525-48 [12475200.001]
  • (PMID = 18392131.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R24CA83099; United States / NCI NIH HHS / CA / P50CA093990; United States / NCI NIH HHS / CA / P01 CA085878; United States / NCI NIH HHS / CA / R24 CA083099; United States / NCI NIH HHS / CA / P01CA85878; United States / NCI NIH HHS / CA / P50 CA093990
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Serine Proteinase Inhibitors; EC 3.4.21.75 / Furin; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  • [Other-IDs] NLM/ PMC2288536
  •  go-up   go-down


27. Turner PC, Loffredo C, Kafrawy SE, Ezzat S, Eissa SA, Daly ME, Nada O, Abdel-Hamid M: Pilot survey of aflatoxin-albumin adducts in sera from Egypt. Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2008 May;25(5):583-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These AF-alb data do not represent a case-control comparison due to inherent difficulties in comparing markers of dietary intake between controls and patients with disease.
  • [MeSH-major] Aflatoxins / blood. Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / blood. Liver Neoplasms / blood. Serum Albumin / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18473213.001).
  • [ISSN] 1944-0057
  • [Journal-full-title] Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment
  • [ISO-abbreviation] Food Addit Contam Part A Chem Anal Control Expo Risk Assess
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES06052; United States / NCI NIH HHS / CA / R01CA85888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aflatoxins; 0 / Albumins; 0 / Biomarkers, Tumor; 0 / Environmental Pollutants; 0 / Serum Albumin; 0 / aflatoxin-albumin adduct
  •  go-up   go-down


28. Zhang YT, Geng YP, Zhou L, Lai BC, Si LS, Wang YL: Identification of proteins of human colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. World J Gastroenterol; 2005 Aug 14;11(30):4679-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To conduct the proteomic analysis of human colorectal carcinoma cell line, SW480 by using two-dimensional electrophoresis (2-DE) and matrix-assisted laser desorption /ionization-time of flight mass spectrometry (MALDI-TOFMS).
  • METHODS: The total proteins of human colorectal carcinoma cell line, SW480 were separated with 2-DE by using immobilized pH gradient strips and visualized by staining with silver nitrate.
  • The gel images were acquired by scanner and 2-DE analysis software, Image Master 2D Elite.
  • CONCLUSION: The methods of analysis and identification of protein spots of tumor cells in 2-DE gel with silver staining by MALDI-TOF MS derived PMF have been established.
  • [MeSH-major] Colorectal Neoplasms / chemistry. Neoplasm Proteins / isolation & purification
  • [MeSH-minor] Amino Acid Sequence. Cell Line, Tumor. Electrophoresis, Gel, Two-Dimensional. Humans. Molecular Sequence Data. Peptide Mapping. Proteome / isolation & purification. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094709.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proteome
  • [Other-IDs] NLM/ PMC4615410
  •  go-up   go-down


29. Ho JA, Chang HC, Shih NY, Wu LC, Chang YF, Chen CC, Chou C: Diagnostic detection of human lung cancer-associated antigen using a gold nanoparticle-based electrochemical immunosensor. Anal Chem; 2010 Jul 15;82(14):5944-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of rapid and sensitive methods for the detection of immunogenic tumor-associated antigen is important not only for understanding their roles in cancer immunology but also for the development of clinical diagnostics.
  • [MeSH-major] Antigens, Neoplasm / analysis. Electrochemical Techniques / methods. Gold / chemistry. Lung Neoplasms / diagnosis. Metal Nanoparticles / chemistry


30. Cervelli M, Bellavia G, Fratini E, Amendola R, Polticelli F, Barba M, Federico R, Signore F, Gucciardo G, Grillo R, Woster PM, Casero RA Jr, Mariottini P: Spermine oxidase (SMO) activity in breast tumor tissues and biochemical analysis of the anticancer spermine analogues BENSpm and CPENSpm. BMC Cancer; 2010 Oct 14;10:555
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spermine oxidase (SMO) activity in breast tumor tissues and biochemical analysis of the anticancer spermine analogues BENSpm and CPENSpm.
  • The inhibition properties shown by these analogues could explain their poor positive outcomes in Phases I and II of clinical trials.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Protein Sci. 1999 Dec;8(12):2621-9 [10631977.001]
  • [Cites] Inflamm Bowel Dis. 2010 Sep;16(9):1557-66 [20127992.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3657-61 [10999758.001]
  • [Cites] Biochem Cell Biol. 2000;78(4):415-26 [11012080.001]
  • [Cites] J Med Chem. 2001 Jan 4;44(1):1-26 [11141084.001]
  • [Cites] Invest New Drugs. 2001;19(1):29-39 [11291831.001]
  • [Cites] Oncogene. 2001 Mar 29;20(14):1715-29 [11313919.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):684-90 [11895896.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):5271-6 [12458219.001]
  • [Cites] Biochem Soc Trans. 2003 Apr;31(2):393-6 [12653646.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 16;304(4):605-11 [12727196.001]
  • [Cites] Biochem J. 2003 Aug 1;373(Pt 3):661-7 [12803540.001]
  • [Cites] J Cell Mol Med. 2003 Apr-Jun;7(2):113-26 [12927050.001]
  • [Cites] Biochem J. 2003 Nov 15;376(Pt 1):1-14 [13678416.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5922-8 [14676116.001]
  • [Cites] Eur J Biochem. 2004 Feb;271(4):760-70 [14764092.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Steroid Biochem Mol Biol. 1990 Sep;37(1):1-10 [2242341.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2424-30 [1568212.001]
  • [Cites] J Mol Biol. 1993 Dec 5;234(3):779-815 [8254673.001]
  • [Cites] Breast Cancer Res Treat. 1994 Feb;29(2):189-201 [8012036.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] Invest New Drugs. 1997;15(3):227-34 [9387045.001]
  • [Cites] Clin Cancer Res. 1995 Aug;1(8):847-57 [9816054.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1901-6 [9816147.001]
  • [Cites] Structure. 1999 Mar 15;7(3):265-76 [10368296.001]
  • [Cites] Biochem J. 1953 Aug;55(1):170-1 [13093635.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8521-5 [15574757.001]
  • [Cites] Oncol Rep. 2005 Jan;13(1):101-8 [15583809.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2986-90 [15837752.001]
  • [Cites] J Mol Biol. 2005 May 13;348(4):951-9 [15843025.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Jul;56(1):83-90 [15791459.001]
  • [Cites] J Biol Chem. 2005 Dec 2;280(48):39843-51 [16207710.001]
  • [Cites] FEBS J. 2006 Mar;273(6):1115-23 [16519678.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11125-30 [17145855.001]
  • [Cites] Nat Rev Drug Discov. 2007 May;6(5):373-90 [17464296.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2008 Mar;40(3):235-43 [18330478.001]
  • [Cites] Prostate. 2008 May 15;68(7):766-72 [18302221.001]
  • [Cites] Curr Cancer Drug Targets. 2009 Mar;9(2):118-30 [19275753.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 May;65(6):1067-81 [19727732.001]
  • [Cites] Endocr Relat Cancer. 1999 Mar;6(1):69-73 [10732790.001]
  • (PMID = 20946629.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098454-06; United States / NCI NIH HHS / CA / R01 CA098454; United States / NCI NIH HHS / CA / R01 CA149095; United States / NCI NIH HHS / CA / R01 CA098454-06
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Polyamines; 0 / Recombinant Proteins; 121749-39-1 / N(1),N(11)-diethylnorspermine; 151915-04-7 / N(1)-ethyl-N-(11)-((cyclopropyl)methyl)-4,8-diazaundecane-1,11-diamine; 2FZ7Y3VOQX / Spermine; EC 1.5.- / Oxidoreductases Acting on CH-NH Group Donors; EC 1.5.3.- / polyamine oxidase
  • [Other-IDs] NLM/ PMC3027604
  •  go-up   go-down


31. Singh B, Mense SM, Remotti F, Liu X, Bhat HK: Antioxidant butylated hydroxyanisole inhibits estrogen-induced breast carcinogenesis in female ACI rats. J Biochem Mol Toxicol; 2009 May-Jun;23(3):202-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cotreatment of rats with E(2) + BHA reduced estrogen-induced breast tumor development with tumor incidence of 24%, a significant decrease relative to E(2) where tumor incidence was 82%.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BUTYLATED HYDROXYANISOLE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Food Chem Toxicol. 1999 Sep-Oct;37(9-10):993-7 [10541456.001]
  • [Cites] Carcinogenesis. 1982;3(1):15-9 [7067033.001]
  • [Cites] Cancer Res. 1982 Jul;42(7):2609-15 [6805943.001]
  • [Cites] Cancer Res. 1982 Aug;42(8):3232-9 [7046921.001]
  • [Cites] Carcinogenesis. 1983;4(2):131-6 [6297821.001]
  • [Cites] Cancer Res. 1984 Jul;44(7):2858-63 [6426789.001]
  • [Cites] J Steroid Biochem. 1986 Jan;24(1):353-6 [3009986.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(14):5301-5 [3460092.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Carcinogenesis. 1990 Apr;11(4):567-70 [1691052.001]
  • [Cites] Free Radic Biol Med. 1990;8(4):415-23 [2199344.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(23):9383-7 [2123555.001]
  • [Cites] Endocrinology. 1992 Aug;131(2):655-61 [1386303.001]
  • [Cites] IARC Sci Publ. 1993;(124):149-55 [8225478.001]
  • [Cites] Carcinogenesis. 1994 May;15(5):997-1000 [8200107.001]
  • [Cites] J Biol Chem. 1995 Apr 28;270(17):9800-8 [7730359.001]
  • [Cites] Cancer Invest. 1995;13(3):287-95 [7743382.001]
  • [Cites] Carcinogenesis. 1995 Aug;16(8):1941-5 [7634425.001]
  • [Cites] Breast Cancer Res Treat. 1997 May;44(1):65-74 [9164679.001]
  • [Cites] Carcinogenesis. 1997 Aug;18(8):1595-601 [9276635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10937-42 [9380738.001]
  • [Cites] Chem Res Toxicol. 1998 Aug;11(8):909-16 [9705753.001]
  • [Cites] Mutat Res. 1999 Mar 8;424(1-2):9-21 [10064846.001]
  • [Cites] Mutat Res. 1999 Mar 8;424(1-2):107-15 [10064854.001]
  • [Cites] J Endocrinol. 2004 Oct;183(1):91-9 [15525577.001]
  • [Cites] FASEB J. 2004 Dec;18(15):1791-800 [15576482.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18123-8 [15601761.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:247-57 [15650250.001]
  • [Cites] Biochemistry. 2005 May 10;44(18):6900-9 [15865435.001]
  • [Cites] Oncogene. 2005 Jul 21;24(31):4883-93 [15897899.001]
  • [Cites] N Engl J Med. 2006 Jan 19;354(3):270-82 [16421368.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):491-8 [16311245.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1292-9 [16537557.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1089:286-301 [17261777.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2007 Jun-Jul;10(4):235-57 [17620201.001]
  • [Cites] Methods Enzymol. 2007;433:113-26 [17954231.001]
  • [Cites] Chem Res Toxicol. 2008 Feb;21(2):276-81 [18189366.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Oct 1;232(1):78-85 [18640140.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):63-78 [16675129.001]
  • [Cites] Endocr Rev. 2000 Feb;21(1):40-54 [10696569.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):67-73 [10963620.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):75-93 [10963621.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):95-112 [10963622.001]
  • [Cites] BMJ. 2000 Sep 9;321(7261):624-8 [10977847.001]
  • [Cites] N Engl J Med. 2001 Jan 25;344(4):276-85 [11172156.001]
  • [Cites] Anal Cell Pathol. 2001;23(1):21-8 [11790856.001]
  • [Cites] Mol Carcinog. 2002 Jan;33(1):56-65 [11807958.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 17;94(8):606-16 [11959894.001]
  • [Cites] Cell Mol Life Sci. 2002 Apr;59(4):665-81 [12022473.001]
  • [Cites] J Endocrinol. 2002 Nov;175(2):297-305 [12429028.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3913-8 [12655060.001]
  • [Cites] J Biochem Mol Toxicol. 2004;18(1):37-42 [14994278.001]
  • [Cites] Free Radic Biol Med. 2004 Aug 1;37(3):287-303 [15223063.001]
  • [Cites] J Natl Cancer Inst. 1977 Feb;58(2):413-7 [833886.001]
  • [Cites] Biochem Biophys Res Commun. 1977 Nov 21;79(2):569-76 [412501.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):427-33 [10688862.001]
  • (PMID = 19526586.001).
  • [ISSN] 1099-0461
  • [Journal-full-title] Journal of biochemical and molecular toxicology
  • [ISO-abbreviation] J. Biochem. Mol. Toxicol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES009089; United States / NCI NIH HHS / CA / R01 CA109551; United States / NCI NIH HHS / CA / CA109551; United States / NIEHS NIH HHS / ES / ES009089
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Estrogens; 25013-16-5 / Butylated Hydroxyanisole; 27415-26-5 / 8-epi-prostaglandin F2alpha; 4TI98Z838E / Estradiol; B7IN85G1HY / Dinoprost
  • [Other-IDs] NLM/ NIHMS591731; NLM/ PMC4094238
  •  go-up   go-down


32. Huang S, Li R, Qu Y, Shen J, Liu J: Fluorescent biological label for recognizing human ovarian tumor cells based on fluorescent nanoparticles. J Fluoresc; 2009 Nov;19(6):1095-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescent biological label for recognizing human ovarian tumor cells based on fluorescent nanoparticles.
  • In this paper, we report a method for recognizing human ovarian tumor (HOT) cells using fluorescent biological label based on core-shell nanoparticles.
  • The fluorescent silica core-shell nanoparticles modified with anti-HER2 antibody using bifunctional cross-linker glutaraldehyde targeted the corresponding tumor antigen in the cell surface of the SKOV3 ovarian cancer cells.
  • [MeSH-major] Nanoparticles. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Autoantibodies. Cell Line, Tumor. Female. Fluorescence. Glutaral. Humans. Microscopy, Confocal. Microscopy, Electron, Scanning. Receptor, ErbB-2 / immunology. Silicon Dioxide. Spectrometry, Fluorescence

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Glutaraldehyde .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 2004 Sep 15;76(18):5302-12 [15362886.001]
  • [Cites] Anal Chem. 2007 Sep 1;79(17):6507-14 [17658763.001]
  • [Cites] Langmuir. 2004 Sep 14;20(19):8336-42 [15350111.001]
  • [Cites] Bioconjug Chem. 2005 May-Jun;16(3):494-6 [15898713.001]
  • [Cites] Anal Chem. 2001 Oct 15;73(20):4988-93 [11681477.001]
  • [Cites] Anal Biochem. 1997 Jun 1;248(2):195-201 [9177744.001]
  • [Cites] J Nanosci Nanotechnol. 2002 Jun-Aug;2(3-4):317-20 [12908257.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):11838-43 [16873550.001]
  • [Cites] Int J Pharm. 2007 Mar 1;331(2):190-6 [17196347.001]
  • [Cites] Nano Lett. 2006 Jan;6(1):84-8 [16402792.001]
  • [Cites] Bioconjug Chem. 2006 Sep-Oct;17(5):1109-15 [16984117.001]
  • [Cites] J Immunol Methods. 2005 Dec 20;307(1-2):34-40 [16263131.001]
  • [Cites] Nano Lett. 2005 Jan;5(1):113-7 [15792423.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Bioconjug Chem. 2004 Mar-Apr;15(2):344-8 [15025530.001]
  • [Cites] Nano Lett. 2005 Jan;5(1):37-43 [15792409.001]
  • [Cites] Anal Chem. 2004 Feb 1;76(3):513-8 [14750841.001]
  • [Cites] J Phys Chem C Nanomater Interfaces. 2007;111(7):2872-2878 [18985164.001]
  • [Cites] Anal Chem. 2006 Feb 15;78(4):1104-6 [16478100.001]
  • [Cites] Oncology. 2005;68(2-3):154-61 [16020953.001]
  • [Cites] Talanta. 2005 Jan 15;65(1):206-10 [18969785.001]
  • [Cites] Anal Biochem. 2006 Jan 15;348(2):321-3 [16307719.001]
  • [Cites] Anal Chem. 2003 Jan 1;75(1):83-90 [12530822.001]
  • [Cites] Lasers Surg Med. 2001;29(2):128-35 [11553899.001]
  • (PMID = 19578986.001).
  • [ISSN] 1573-4994
  • [Journal-full-title] Journal of fluorescence
  • [ISO-abbreviation] J Fluoresc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantibodies; 7631-86-9 / Silicon Dioxide; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; T3C89M417N / Glutaral
  •  go-up   go-down


33. Zhai Z, Liu Y, Wu L, Senchina DS, Wurtele ES, Murphy PA, Kohut ML, Cunnick JE: Enhancement of innate and adaptive immune functions by multiple Echinacea species. J Med Food; 2007 Sep;10(3):423-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The three herbal extracts significantly increased interferon-alpha production, but inhibited the release of tumor necrosis factor-gamma and interleukin (IL)-1beta.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharm Pharmacol. 2001 Jun;53(6):849-57 [11428661.001]
  • [Cites] Exp Gerontol. 2000 Aug;35(5):627-39 [10978684.001]
  • [Cites] Biochem Pharmacol. 2000 Jul 15;60(2):155-8 [10825459.001]
  • [Cites] J Agric Food Chem. 2000 May;48(5):1466-72 [10820044.001]
  • [Cites] J Pharm Biomed Anal. 2004 Apr 16;35(2):289-301 [15063463.001]
  • [Cites] Biol Pharm Bull. 2004 Jul;27(7):1004-9 [15256730.001]
  • [Cites] Phytochemistry. 2004 Sep;65(17):2477-84 [15381412.001]
  • [Cites] Immunology. 1968 Apr;14(4):599-600 [5653817.001]
  • [Cites] Infect Immun. 1984 Dec;46(3):845-9 [6389368.001]
  • [Cites] Cell Immunol. 1990 Apr 1;126(2):278-89 [2311123.001]
  • [Cites] Int J Immunopharmacol. 1991;13(1):27-37 [2026472.001]
  • [Cites] Alcohol Clin Exp Res. 1992 Apr;16(2):331-5 [1590554.001]
  • [Cites] Alcohol Clin Exp Res. 1993 Feb;17(1):75-85 [8452211.001]
  • [Cites] J Exp Med. 1995 Feb 1;181(2):537-46 [7836910.001]
  • [Cites] Immunopharmacology. 1997 Jan;35(3):229-35 [9043936.001]
  • [Cites] Int J Immunopharmacol. 1997 Jul;19(7):371-9 [9568541.001]
  • [Cites] Cytokine. 1998 Jun;10(6):395-403 [9632524.001]
  • [Cites] Am Fam Physician. 1998 Oct 1;58(5):1133-40 [9787279.001]
  • [Cites] Immunol Lett. 1999 Jun 1;68(2-3):391-5 [10424448.001]
  • [Cites] Contemp Top Lab Anim Sci. 2004 Nov;43(6):42-51 [15669134.001]
  • [Cites] Clin Infect Dis. 2005 Mar 15;40(6):807-10 [15736012.001]
  • [Cites] South Med J. 2005 Mar;98(3):311-8 [15813158.001]
  • [Cites] Clin Chim Acta. 2005 May;355(1-2):67-82 [15820480.001]
  • [Cites] Fitoterapia. 2005 Jul;76(5):401-11 [15949903.001]
  • [Cites] J Agric Food Chem. 2005 Nov 30;53(24):9413-23 [16302756.001]
  • [Cites] J Altern Complement Med. 2001 Jun;7(3):241-51 [11439845.001]
  • [Cites] J Ethnopharmacol. 2002 Feb;79(2):265-72 [11801391.001]
  • [Cites] J Altern Complement Med. 2002 Feb;8(1):49-58 [11890433.001]
  • [Cites] Equine Vet J. 2002 May;34(3):222-7 [12108738.001]
  • [Cites] J Pharm Pharmacol. 2002 Oct;54(10):1379-83 [12396300.001]
  • [Cites] Phytomedicine. 2002 Oct;9(7):606-13 [12487324.001]
  • [Cites] Planta Med. 2002 Dec;68(12):1118-24 [12494341.001]
  • [Cites] Life Sci. 2003 Feb 14;72(13):1495-508 [12535717.001]
  • [Cites] Phytomedicine. 2003 Jan;10(1):66-86 [12622467.001]
  • [Cites] Int Immunopharmacol. 2003 Jul;3(7):1041-8 [12810361.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Oct;228(9):1051-6 [14530514.001]
  • [Cites] Immunopharmacol Immunotoxicol. 2003 Nov;25(4):551-60 [14686797.001]
  • (PMID = 17887935.001).
  • [ISSN] 1096-620X
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES012020-05; United States / NIEHS NIH HHS / ES / P01 ES012020; United States / NIEHS NIH HHS / ES / P01 ES012020-05; United States / NIEHS NIH HHS / ES / P01ES012020
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Mitogens; 0 / Plant Extracts
  • [Other-IDs] NLM/ NIHMS41071; NLM/ PMC2362099
  •  go-up   go-down


34. Kang HW, Ida K, Yamamoto Y, Muramatsu H: Monitoring of morphology and physical properties of cultured cells using a micro camera and a quartz crystal with transparent indium tin oxide electrodes after injections of glutaraldehyde and trypsin. Anal Chim Acta; 2008 Aug 22;624(1):154-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Cell Adhesion / physiology. Cell Line, Tumor. Edetic Acid / pharmacology. Extracellular Matrix / chemistry. Glutaral / pharmacology. Humans. Microelectrodes. Photography / instrumentation. Trypsin / pharmacology

  • Hazardous Substances Data Bank. TIN COMPOUNDS .
  • Hazardous Substances Data Bank. Glutaraldehyde .
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18706321.001).
  • [ISSN] 1873-4324
  • [Journal-full-title] Analytica chimica acta
  • [ISO-abbreviation] Anal. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tin Compounds; 14808-60-7 / Quartz; 71243-84-0 / indium tin oxide; 9G34HU7RV0 / Edetic Acid; EC 3.4.21.4 / Trypsin; T3C89M417N / Glutaral
  •  go-up   go-down


35. Jin YX, Shi LH, Yoo HS, Lee YM, Kihara A, Igarashi Y, So HY, Yim YH: A sphingosine kinase activity assay using direct infusion electrospray ionization tandem mass spectrometry. Anal Biochem; 2008 Sep 1;380(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Cattle. Cell Line, Tumor. Enzyme Activation / drug effects. Enzyme Inhibitors / pharmacology. Mice. Reproducibility of Results. Sphingosine / analogs & derivatives. Sphingosine / pharmacology. Tetradecanoylphorbol Acetate / analogs & derivatives. Tetradecanoylphorbol Acetate / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541132.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 122314-67-4 / N,N-dimethylsphingosine; 56937-68-9 / phorbolol myristate acetate; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.- / sphingosine kinase; NGZ37HRE42 / Sphingosine; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


36. Oršolić N, Benković V, Lisičić D, Dikić D, Erhardt J, Knežević AH: Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan. Med Oncol; 2010 Dec;27(4):1346-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was carried out to find whether propolis preparations and related flavonoids (quercetin, naringin) might enhance irinotecan-induced cytotoxicity to tumor cells in mice bearing Ehrlich ascites tumors (EAT) while protecting normal blood, liver, and kidney cells.
  • Irinotecan was administered ip at dose of 50 mg kg(-1) on days 3, 4, and 5 after tumor cell inoculation.
  • However, when mice were pre-treated with test components prior to irinotecan, the frequencies of irinotecan-induced micronuclei (MN) was decreased but in mice bearing tumor QU and EEP increased number of micronucleated cells.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / toxicity. Camptothecin / analogs & derivatives. Carcinoma, Ehrlich Tumor / drug therapy. Flavonoids / therapeutic use. Immunologic Factors / therapeutic use. Phenols / therapeutic use. Propolis / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2004 Nov;134(11):3201S-3204S [15514307.001]
  • [Cites] Exp Cell Res. 1973 Mar 15;77(1):323-34 [4570355.001]
  • [Cites] Environ Health Perspect. 1994 Jan;102 Suppl 1:49-52 [8187724.001]
  • [Cites] Antioxid Redox Signal. 2002 Feb;4(1):97-104 [11970847.001]
  • [Cites] Drugs Exp Clin Res. 1987;13(10):593-9 [3428123.001]
  • [Cites] Phytochem Anal. 2004 Jul-Aug;15(4):235-40 [15311843.001]
  • [Cites] J Ethnopharmacol. 2007 Aug 15;113(1):1-14 [17580109.001]
  • [Cites] Xenobiotica. 1994 Jul;24(7):689-99 [7975732.001]
  • [Cites] J Am Coll Nutr. 2001 Dec;20(6):628-36 [11771679.001]
  • [Cites] Altern Med Rev. 2000 Apr;5(2):152-63 [10767670.001]
  • [Cites] Semin Oncol. 1992 Dec;19(6 Suppl 13):3-9 [1492225.001]
  • [Cites] Integr Cancer Ther. 2004 Dec;3(4):333-41 [15523104.001]
  • [Cites] Evid Based Complement Alternat Med. 2004 Sep 1;1(2):175-185 [15480443.001]
  • [Cites] Adv Nephrol Necker Hosp. 1988;17:175-218 [3124539.001]
  • [Cites] Exp Mol Pathol. 1995 Jun;62(3):190-8 [8612723.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):461-8 [12216075.001]
  • [Cites] Toxicology. 2004 Feb 15;195(2-3):87-95 [14751666.001]
  • [Cites] Braz J Med Biol Res. 2002 Jul;35(7):819-22 [12131922.001]
  • [Cites] Acta Pharm. 2003 Dec;53(4):275-85 [14769234.001]
  • [Cites] Food Chem Toxicol. 2002 Jul;40(7):941-7 [12065216.001]
  • [Cites] Planta Med. 2006 Jan;72(1):20-7 [16450291.001]
  • [Cites] Biol Pharm Bull. 2005 Feb;28(2):364-6 [15684501.001]
  • [Cites] Biochem Pharmacol. 2006 Oct 16;72 (8):1010-21 [16934226.001]
  • [Cites] Biomed Pharmacother. 2007 Jun;61(5):292-7 [17412551.001]
  • [Cites] Biol Pharm Bull. 2005 Apr;28(4):694-700 [15802812.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1606-14 [16533788.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2005 Jan;140(1):69-78 [15792625.001]
  • [Cites] J Nat Prod. 1995 Feb;58(2):217-25 [7769390.001]
  • [Cites] Biochem J. 2004 Dec 15;384(Pt 3):527-41 [15312049.001]
  • [Cites] Biosci Biotechnol Biochem. 2003 Jun;67(6):1215-22 [12843645.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Oct;17(5):553-62 [12470425.001]
  • [Cites] Mutat Res. 1997 Jun 13;391(1-2):87-9 [9219552.001]
  • [Cites] Inflammation. 1990 Feb;14(1):125-32 [2323805.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5841-4 [2168283.001]
  • [Cites] Semin Oncol. 1982 Mar;9(1):95-102 [7071611.001]
  • [Cites] Biomed Pharmacother. 2005 Dec;59(10):561-70 [16202559.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34 Suppl:S69-75 [8070031.001]
  • [Cites] Acta Pharm. 2004 Mar;54(1):65-72 [15050046.001]
  • [Cites] Am J Clin Nutr. 1998 Dec;68(6 Suppl):1375S-1379S [9848502.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2006 Jul;143(3):349-54 [16720105.001]
  • [Cites] Cell Immunol. 1977 Mar 1;29(1):86-95 [849607.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34 Suppl:S64-8 [8070030.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Dec;299(3):915-20 [11714876.001]
  • [Cites] Lancet. 1993 Oct 23;342(8878):1007-11 [8105262.001]
  • (PMID = 20013318.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Immunologic Factors; 0 / Phenols; 0H43101T0J / irinotecan; 9009-62-5 / Propolis; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


37. Wilfred de Alwis NM, Day CP: Genes and nonalcoholic fatty liver disease. Curr Diab Rep; 2008 Apr;8(2):156-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genes and nonalcoholic fatty liver disease.
  • Whereas most individuals with nonalcoholic fatty liver disease (NAFLD) will have steatosis, only a minority will ever develop progressive disease.
  • Family studies and interethnic variations in susceptibility suggest that genetic factors may be important in determining disease risk.
  • Although no genetic associations with advanced NAFLD have been replicated in large studies, preliminary data suggest that polymorphisms in the genes encoding microsomal triglyceride transfer protein, superoxide dismutase 2, the CD14 endotoxin receptor, tumor necrosis factor-alpha, transforming growth factor-beta, and angiotensinogen may be associated with steatohepatitis and/or fibrosis.
  • With the advent of high-throughput gene analyses and the reduced cost of whole genome-wide scans, it seems likely that genes contributing to inherited susceptibility to this common disease will be identified in the near future.
  • [MeSH-minor] Animals. Carcinoma, Hepatocellular / genetics. Cytokines / genetics. Fatty Acids, Nonesterified / analysis. Female. Humans. Liver / metabolism. Liver Neoplasms / genetics. Male. Oligonucleotide Array Sequence Analysis. Oxidative Stress. Polymorphism, Genetic. Proteomics. Risk Factors. Sex Characteristics

  • Genetic Alliance. consumer health - Liver Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2002 Nov;8(11):1288-95 [12368907.001]
  • [Cites] Hepatology. 2005 Sep;42(3):665-74 [16116632.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2957-61 [11693332.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2631-5 [15713713.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):91-100 [11438497.001]
  • [Cites] Hepatology. 2004 Jul;40(1):46-54 [15239085.001]
  • [Cites] J Biol Chem. 1998 Jun 19;273(25):15639-45 [9624157.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 May;20(5):976-83 [10226067.001]
  • [Cites] Gastroenterology. 2006 Jan;130(1):207-10 [16401483.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1649-57 [12016429.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):663-78 [12406438.001]
  • [Cites] Anal Chem. 2003 Apr 1;75(7):148A-55A [19530659.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1366-74 [17476695.001]
  • [Cites] J Hepatol. 2006 Jun;44(6):1196-207 [16618516.001]
  • [Cites] Diabetologia. 2000 Aug;43(8):995-9 [10990076.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1496-500 [12094872.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1443-8 [15033905.001]
  • [Cites] J Clin Invest. 2003 Jul;112(1):91-100 [12840063.001]
  • [Cites] J Hepatol. 2007 May;46(5):915-20 [17391797.001]
  • [Cites] Mayo Clin Proc. 1980 Jul;55(7):434-8 [7382552.001]
  • [Cites] Hepatology. 2003 Apr;37(4):909-16 [12668986.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1463-6 [9620314.001]
  • [Cites] Hepatology. 2004 Jan;39(1):179-87 [14752836.001]
  • [Cites] J Hepatol. 2007 Jun;46(6):1104-10 [17395331.001]
  • [Cites] Br J Clin Pharmacol. 2001 Nov;52(5):489-99 [11736857.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):311-8 [9453491.001]
  • [Cites] Am J Gastroenterol. 2004 Feb;99(2):292-8 [15046220.001]
  • [Cites] J Hepatol. 2008;48 Suppl 1:S104-12 [18304679.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2844-52 [16510607.001]
  • [Cites] Hepatology. 2003 Mar;37(3):493-503 [12601343.001]
  • [Cites] Am J Med. 2000 Jan;108(1):9-13 [11059435.001]
  • [Cites] Hepatology. 2003 Jul;38(1):244-51 [12830008.001]
  • [Cites] Hepatology. 2003 May;37(5):1202-19 [12717402.001]
  • [Cites] Hepatology. 1990 Nov;12(5):1106-10 [2227807.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):274-80 [11832442.001]
  • [Cites] Gut. 2001 Feb;48(2):206-11 [11156641.001]
  • [Cites] J Hepatol. 2004 May;40(5):781-6 [15094225.001]
  • [Cites] Dig Dis Sci. 2005 Dec;50(12):2338-43 [16416185.001]
  • [Cites] Endocrinology. 2003 Sep;144(9):3914-21 [12933665.001]
  • [Cites] Clin Liver Dis. 2007 Feb;11(1):209-20, xi [17544980.001]
  • [Cites] J Hepatol. 2007 Apr;46(4):708-18 [17275126.001]
  • [Cites] Hepatology. 2007 Sep;46(3):723-9 [17680648.001]
  • [Cites] Diabetes Care. 2007 May;30(5):1212-8 [17277038.001]
  • [Cites] J Hepatol. 2003 Dec;39(6):967-71 [14642613.001]
  • [Cites] Hepatology. 2007 Jul;46(1):166-72 [17596878.001]
  • [Cites] Liver Int. 2005 Aug;25(4):760-71 [15998427.001]
  • (PMID = 18445359.001).
  • [ISSN] 1539-0829
  • [Journal-full-title] Current diabetes reports
  • [ISO-abbreviation] Curr. Diab. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Fatty Acids, Nonesterified
  • [Number-of-references] 51
  •  go-up   go-down


38. Shah MY, Vasanthakumar A, Barnes NY, Figueroa ME, Kamp A, Hendrick C, Ostler KR, Davis EM, Lin S, Anastasi J, Le Beau MM, Moskowitz IP, Melnick A, Pytel P, Godley LA: DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res; 2010 Jul 15;70(14):5840-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis.
  • These data represent the first in vivo modeling of cancer-associated DNA methylation changes and suggest that truncated DNMT3B isoforms contribute to the redistribution of DNA methylation characterizing virtually every human tumor.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] EMBO J. 2005 Jan 26;24(2):336-46 [15616584.001]
  • [Cites] Anal Chem. 2005 Jan 15;77(2):504-10 [15649046.001]
  • [Cites] J Cell Biochem. 2005 Aug 1;95(5):902-17 [15861382.001]
  • [Cites] Development. 2006 Mar;133(6):1183-92 [16501171.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):201-7 [16773201.001]
  • [Cites] Genome Res. 2006 Aug;16(8):1046-55 [16809668.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8361-6 [16951144.001]
  • [Cites] Semin Cancer Biol. 2006 Aug;16(4):253-64 [16904903.001]
  • [Cites] Cell. 2007 Feb 23;128(4):669-81 [17320505.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5553-63 [17353906.001]
  • [Cites] Nature. 2007 Sep 13;449(7159):248-51 [17713477.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10647-52 [18006804.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):404-8 [17621273.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):657-63 [18245464.001]
  • [Cites] J Med Genet. 2008 Feb;45(2):93-9 [17893117.001]
  • [Cites] Epigenetics. 2008 May-Jun;3(3):134-42 [18487951.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9525-31 [19010929.001]
  • [Cites] Dis Model Mech. 2008 Jul-Aug;1(1):37-42 [19048051.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):178-86 [19151715.001]
  • [Cites] Methods Mol Biol. 2009;538:395-407 [19277580.001]
  • [Cites] Blood. 2009 Oct 15;114(16):3448-58 [19652201.001]
  • [Cites] Mol Cancer Res. 2009 Oct;7(10):1622-34 [19825994.001]
  • [Cites] Nat Genet. 2009 Nov;41(11):1207-15 [19801979.001]
  • [Cites] Cancer Res. 2009 Dec 1;69(23):9038-46 [19887623.001]
  • [Cites] Cancer Res. 2009 Dec 1;69(23):9073-82 [19887624.001]
  • [Cites] Blood. 2009 Dec 24;114(27):5490-8 [19855078.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):13-27 [20060365.001]
  • [Cites] Cell. 1999 Oct 29;99(3):247-57 [10555141.001]
  • [Cites] J Immunol Methods. 1999 Aug 31;228(1-2):131-8 [10556550.001]
  • [Cites] Hum Mol Genet. 2000 Oct;9(16):2395-402 [11005794.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2985-91 [11929790.001]
  • [Cites] Development. 2002 Apr;129(8):1983-93 [11934864.001]
  • [Cites] Nat Rev Genet. 2002 Sep;3(9):662-73 [12209141.001]
  • [Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]
  • [Cites] J Androl. 2003 Nov-Dec;24(6):822-30 [14581508.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):533-8 [3906410.001]
  • [Cites] J Exp Med. 1988 Feb 1;167(2):353-71 [3258007.001]
  • [Cites] Lab Anim Sci. 1990 Jul;40(4):418-9 [2166875.001]
  • [Cites] Cell. 1992 Jun 12;69(6):915-26 [1606615.001]
  • [Cites] Oncogene. 2005 Jun 16;24(26):4174-82 [15824738.001]
  • (PMID = 20587527.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129831-01A1; United States / NCI NIH HHS / CA / R01 CA129831; United States / NCI NIH HHS / CA / CA129831-02; United States / NCI NIH HHS / CA / R01 CA129831-02; United States / NCI NIH HHS / CA / R01 CA129831-03; United States / NCI NIH HHS / CA / CA129831-03; United States / NCI NIH HHS / CA / R01 CA129831-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3B
  • [Other-IDs] NLM/ NIHMS211281; NLM/ PMC2905468
  •  go-up   go-down


39. Thomson DM, Hancock CR, Evanson BG, Kenney SG, Malan BB, Mongillo AD, Brown JD, Hepworth S, Fillmore N, Parcell AC, Kooyman DL, Winder WW: Skeletal muscle dysfunction in muscle-specific LKB1 knockout mice. J Appl Physiol (1985); 2010 Jun;108(6):1775-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver kinase B1 (LKB1) is a tumor-suppressing protein that is involved in the regulation of muscle metabolism and growth by phosphorylating and activating AMP-activated protein kinase (AMPK) family members.

  • MedlinePlus Health Information. consumer health - Muscle Disorders.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Appl Physiol (1985). 2008 Jan;104(1):27-33 [17885021.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1572-9 [17925454.001]
  • [Cites] J Appl Physiol (1985). 2008 Mar;104(3):625-32 [18187610.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2446-59 [18227154.001]
  • [Cites] J Physiol. 2008 Mar 15;586(6):1731-41 [18202101.001]
  • [Cites] Diabetes. 2008 Apr;57(4):860-7 [18184930.001]
  • [Cites] Cell Mol Life Sci. 2008 Nov;65(23):3737-55 [18810325.001]
  • [Cites] J Physiol. 2008 Dec 15;586(Pt 24):6021-35 [18955383.001]
  • [Cites] J Biol Chem. 2009 Dec 18;284(51):35839-49 [19828446.001]
  • [Cites] J Cell Biol. 2009 Dec 14;187(6):859-74 [20008564.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2010 Apr;298(4):E761-9 [20051528.001]
  • [Cites] J Appl Physiol (1985). 2000 Jun;88(6):2219-26 [10846039.001]
  • [Cites] Circulation. 2000 Oct 10;102(15):1847-53 [11023942.001]
  • [Cites] Science. 2001 Aug 17;293(5533):1323-6 [11509733.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):23977-80 [11997383.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 May;284(5):E1001-8 [12582012.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Jun;284(6):C1669-77 [12734114.001]
  • [Cites] EMBO J. 2004 Feb 25;23(4):833-43 [14976552.001]
  • [Cites] J Histochem Cytochem. 1970 Sep;18(9):670-2 [4249441.001]
  • [Cites] J Chromatogr Sci. 1977 Jun;15(6):218-21 [881468.001]
  • [Cites] Am J Physiol. 1990 Feb;258(2 Pt 1):C258-65 [2305868.001]
  • [Cites] J Muscle Res Cell Motil. 1991 Feb;12(1):37-44 [2050810.001]
  • [Cites] Anal Biochem. 1992 Aug 1;204(2):383-9 [1443539.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):184-7 [9428765.001]
  • [Cites] Circ Res. 2005 Apr 29;96(8):838-46 [15790954.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jun;288(6):C1287-97 [15659712.001]
  • [Cites] EMBO J. 2005 May 18;24(10):1810-20 [15889149.001]
  • [Cites] Int J Sports Med. 2006 Feb;27(2):94-9 [16475053.001]
  • [Cites] Pflugers Arch. 2006 Sep;452(6):653-66 [16767467.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(22):8217-27 [16966378.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16260-5 [17053067.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E196-202 [16926377.001]
  • [Cites] Am J Pathol. 2007 Feb;170(2):599-608 [17255328.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):316-23 [17277771.001]
  • [Cites] Nat Med. 2007 May;13(5):597-603 [17468767.001]
  • [Cites] J Biol Chem. 2007 Oct 12;282(41):30014-21 [17702743.001]
  • [Cites] J Appl Physiol (1985). 2008 Feb;104(2):429-38 [18063805.001]
  • (PMID = 20360428.001).
  • [ISSN] 1522-1601
  • [Journal-full-title] Journal of applied physiology (Bethesda, Md. : 1985)
  • [ISO-abbreviation] J. Appl. Physiol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR-51928
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Stk11 protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2886679
  •  go-up   go-down


40. Bartusik D, Tomanek B: Detection of fluorine labeled herceptin using cellular (19)F MRI ex vivo. J Pharm Biomed Anal; 2010 Mar 11;51(4):894-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Breast Neoplasms / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bioreactors. Cell Line, Tumor. Cell Survival / drug effects. Chemistry, Pharmaceutical. Contrast Media. Dose-Response Relationship, Drug. Emulsions. Female. Fluorocarbons. Humans. Inhibitory Concentration 50. Lipids / chemistry. Time Factors. Trastuzumab

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. Trastuzumab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19896315.001).
  • [ISSN] 1873-264X
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Emulsions; 0 / Fluorocarbons; 0 / Lipids; 0 / Lipofectamine; P188ANX8CK / Trastuzumab; Q1D0Q7R4D9 / perflubron
  •  go-up   go-down


41. Kim KT, Na CH, Yun YM, Hwang TS, Kim SN, Chae CB: Dramatic increase in signal by integration of polymerase chain reaction and hybridization on surface of DNA microarray. Anal Biochem; 2010 Jan 1;396(1):139-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cumbersome process required for diagnosis by DNA microarray can be simplified by simple extraction of nucleic acid from cells and by integration of liquid-phase polymerase chain reaction (PCR) and hybridization on the surface of a microarray slide.
  • An unexpected benefit was the large (five- to sixfold) increase in detection signal that also is translated into an increase in sensitivity and the confidence level of diagnosis.
  • The process described in this article saves labor, time, and cost and should be applicable for automation of diagnosis by DNA microarray.
  • [MeSH-minor] Anthracenes / metabolism. Base Sequence. Cell Extracts. Cell Line, Tumor. Cervix Uteri / pathology. Cervix Uteri / virology. DNA / isolation & purification. DNA Probes / metabolism. Female. Genome, Human / genetics. Genotype. Human papillomavirus 16 / genetics. Human papillomavirus 16 / isolation & purification. Humans. Molecular Sequence Data. Mutation / genetics. Polymorphism, Single Nucleotide / genetics. Sensitivity and Specificity. Surface Properties

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19720042.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracenes; 0 / Cell Extracts; 0 / DNA Probes; 0 / dendron; 9007-49-2 / DNA
  •  go-up   go-down


42. Li H, Li Q, Wang X, Xu K, Chen Z, Gong X, Liu X, Tong L, Tang B: Simultaneous determination of superoxide and hydrogen peroxide in macrophage RAW 264.7 cell extracts by microchip electrophoresis with laser-induced fluorescence detection. Anal Chem; 2009 Mar 15;81(6):2193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Cell Line, Tumor. Fluoresceins / chemistry. Macrophages / metabolism. Mice. Reactive Oxygen Species / metabolism

  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19206207.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluoresceins; 0 / Fluorescent Dyes; 0 / Reactive Oxygen Species; 0 / bis(p-methylbenzenesulfonyl)dichlorofluorescein; 11062-77-4 / Superoxides; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


43. Milbury CA, Li J, Makrigiorgos GM: COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations. Clin Chem; 2009 Dec;55(12):2130-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Mutation-containing cell-line DNA serially diluted into wild-type DNA and DNA samples from human lung adenocarcinomas containing low-level mutations were amplified via COLD-PCR and via conventional PCR for TP53 (tumor protein p53) exons 6-8, and the 2 approaches were compared.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2007 Jul;53(7):1191-8 [17525106.001]
  • [Cites] BMC Cancer. 2007;7:168 [17764544.001]
  • [Cites] Nucleic Acids Res. 2007;35(19):e127 [17897966.001]
  • [Cites] Clin Chem. 2008 Jan;54(1):108-15 [17981920.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):487-93 [17908804.001]
  • [Cites] Hum Mutat. 2008 May;29(5):757-64 [18348286.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1236-43 [18308387.001]
  • [Cites] Nat Med. 2008 May;14(5):579-84 [18408729.001]
  • [Cites] Clin Chem. 2008 Jun;54(6):982-9 [18403564.001]
  • [Cites] BMC Cancer. 2008;8:142 [18495026.001]
  • [Cites] Exp Mol Pathol. 2008 Aug;85(1):50-8 [18502416.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4751-7 [18676744.001]
  • [Cites] Leukemia. 2009 Feb;23(2):396-9 [18615105.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2076-84 [19276259.001]
  • [Cites] Clin Chem. 2009 Apr;55(4):632-40 [19201784.001]
  • [Cites] Clin Chem. 2009 Apr;55(4):748-56 [19233916.001]
  • [Cites] Mod Pathol. 2009 May;22(5):718-24 [19287459.001]
  • [Cites] Hum Mutat. 2009 Nov;30(11):1583-90 [19760750.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5385-90 [17875767.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] Clin Chem. 2003 Jun;49(6 Pt 1):853-60 [12765979.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):961-70 [12837832.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):211-6 [15269297.001]
  • [Cites] Clin Chem. 2004 Oct;50(10):1748-54 [15308590.001]
  • [Cites] Oncogene. 1998 May 14;16(19):2469-77 [9627113.001]
  • [Cites] Cell Mol Life Sci. 1999 Jan;55(1):64-75 [10065152.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41 [10430926.001]
  • [Cites] Anal Biochem. 2005 May 1;340(1):24-34 [15802126.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):413-21 [16049314.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1770-7 [16189378.001]
  • [Cites] Clin Chem. 2006 Mar;52(3):494-503 [16423901.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):608-15 [16938658.001]
  • [Cites] BMC Cancer. 2006;6:295 [17184525.001]
  • [CommentIn] Clin Chem. 2009 Dec;55(12):2077-8 [19833831.001]
  • (PMID = 19815609.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA138280; United States / NCI NIH HHS / CA / CA138280-01; United States / NCI NIH HHS / CA / R21 CA111994; United States / NCI NIH HHS / CA / R33 CA111994; United States / NCI NIH HHS / CA / T32 CA009078; United States / NCI NIH HHS / CA / CA-111994; United States / NCI NIH HHS / CA / T32-CA009078; United States / NCI NIH HHS / CA / CA-138280; United States / NCI NIH HHS / CA / R21 CA138280-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS169975; NLM/ PMC2828872
  •  go-up   go-down


44. Bedin V, Adam RL, de Sá BC, Landman G, Metze K: Fractal dimension of chromatin is an independent prognostic factor for survival in melanoma. BMC Cancer; 2010;10:260
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Prognostic factors in malignant melanoma are currently based on clinical data and morphologic examination.
  • Previous studies have demonstrated that fractal characteristics of nuclear chromatin are of prognostic importance in neoplasias.
  • We have therefore investigated whether the fractal dimension of nuclear chromatin measured in routine histological preparations of malignant melanomas could be a prognostic factor for survival.
  • Clark's level, tumor thickness and mitotic rate were also determined.
  • Tumor thickness, Clark's level, mitotic rate, nuclear area and fractal dimension were significant risk factors in univariate Cox regressions.
  • In the multivariate Cox regression, stratified for the presence or absence of metastases at diagnosis, only the Clark level and fractal dimension of the nuclear chromatin were included as independent prognostic factors in the final regression model.
  • CONCLUSION: In general, a more aggressive behaviour is usually found in genetically unstable neoplasias with a higher number of genetic or epigenetic changes, which on the other hand, provoke a more complex chromatin rearrangement.
  • So, there is strong evidence that the fractal dimension of the nuclear chromatin texture is a new and promising variable in prognostic models of malignant melanomas.
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromatin / pathology. Chromatin Assembly and Disassembly. Fractals. Image Processing, Computer-Assisted. Melanoma / mortality. Melanoma / pathology. Skin Neoplasms / pathology


45. Chen S, Ye J, Kijima I, Evans D: The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci U S A; 2010 Jun 15;107(24):11032-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of aromatase in breast cancer tissue is driven by different promoters than those in noncancer tissues; thus, suppression of aromatase expression in cancer tissues through the down-regulation of breast tumor-specific promoters would reduce the side effects associated with whole-body suppression of estrogen biosynthesis by AIs.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LETROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5960-7 [16740737.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5781-9 [16740717.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10281-6 [17079446.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3096-104 [17172412.001]
  • [Cites] Nat Biotechnol. 2007 Jan;25(1):84-90 [17211407.001]
  • [Cites] Cancer Biol Ther. 2007 Jan;6(1):64-9 [17172825.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5541-52 [17694093.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4882-90 [17699868.001]
  • [Cites] Mol Cancer Ther. 2007 Sep;6(9):2515-24 [17876048.001]
  • [Cites] Mol Cancer Res. 2007 Oct;5(10):981-9 [17951399.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7237-42 [18094401.001]
  • [Cites] Blood. 2008 May 15;111(10):5093-100 [18349321.001]
  • [Cites] Mol Cancer Res. 2008 May;6(5):873-83 [18505931.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4455-64 [18519709.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] J Biol Chem. 2008 Jul 25;283(30):21065-73 [18499657.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7561-9 [18794144.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6469-77 [18927286.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):9-14 [19118027.001]
  • [Cites] Mol Cell Endocrinol. 2009 Mar 5;300(1-2):115-20 [19026713.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):3802-9 [19366799.001]
  • [Cites] Cancer Lett. 2009 Aug 8;280(2):233-41 [19344997.001]
  • [Cites] Clin Cancer Res. 2009 Jun 1;15(11):3705-15 [19458058.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3947-57 [19509170.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3970-7 [19509171.001]
  • [Cites] Blood. 2009 Jul 9;114(2):380-93 [19383971.001]
  • [Cites] Leukemia. 2009 Dec;23(12):2265-74 [19812608.001]
  • [Cites] BMC Med Genomics. 2009;2:67 [19948057.001]
  • [Cites] Br J Cancer. 2005 Aug;93 Suppl 1:S16-22 [16100521.001]
  • [Cites] Arch Biochem Biophys. 1999 Nov 15;371(2):179-90 [10545204.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1338-46 [11245431.001]
  • [Cites] Oncogene. 2002 Apr 25;21(18):2854-63 [11973645.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18649-57 [11901151.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5 [12189205.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):219-24 [14623514.001]
  • [Cites] Cell. 2003 Dec 12;115(6):727-38 [14675537.001]
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1081-92 [15014181.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Aug;53(2):412-7 [7251819.001]
  • [Cites] DNA. 1988 Jan-Feb;7(1):27-38 [3390233.001]
  • [Cites] Steroids. 1987 Jul-Sep;50(1-3):269-79 [3509763.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6949-54 [2208160.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Dec 15;189(2):1001-7 [1472013.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11312-6 [8248245.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Dec;77(6):1622-8 [8117355.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2344-9 [8964875.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Nov;81(11):3843-9 [8923826.001]
  • [Cites] J Steroid Biochem Mol Biol. 1996 Oct;59(2):163-71 [9010331.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):175-84 [9365188.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Sep-Oct;63(1-3):29-36 [9449203.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5695-700 [9865725.001]
  • [Cites] Lancet. 2005 Jan 1-7;365(9453):60-2 [15639680.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71 [16145047.001]
  • [Cites] Endocrinology. 2006 Feb;147(2):865-74 [16282359.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):1041-50 [16152586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15540-5 [17030815.001]
  • (PMID = 20534486.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES008258-11; United States / NIEHS NIH HHS / ES / R01 ES008258; United States / NCI NIH HHS / CA / CA44735; United States / NCI NIH HHS / CA / R01 CA044735; United States / NCI NIH HHS / CA / R01 CA044735-20; United States / PHS HHS / / KG080161
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / DNA Primers; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Indoles; 0 / Nitriles; 0 / Triazoles; 142662-43-9 / CCAAT-Enhancer-Binding Protein-delta; 7LKK855W8I / letrozole; 9647FM7Y3Z / panobinostat; EC 1.14.14.1 / Aromatase
  • [Other-IDs] NLM/ PMC2890707
  •  go-up   go-down


46. Austin CD, Wen X, Gazzard L, Nelson C, Scheller RH, Scales SJ: Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci U S A; 2005 Dec 13;102(50):17987-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibody-drug conjugate therapy entails targeted killing of cancer cells with cytotoxic compounds covalently linked to tumor-specific antibodies and shows promise in the treatment of several human cancers.
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Benzoquinones. Cell Line, Tumor. Disulfides / metabolism. Flow Cytometry. Green Fluorescent Proteins. Humans. Lactams, Macrocyclic. Microscopy, Fluorescence. Oxidation-Reduction. Quinones. Rhodamines. Spectrometry, Fluorescence. Trastuzumab

  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):745-50 [10639150.001]
  • [Cites] Expert Opin Pharmacother. 2005 Aug;6(9):1477-91 [16086636.001]
  • [Cites] Antioxid Redox Signal. 2000 Winter;2(4):851-78 [11213489.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 1:S9-13 [11521729.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1361-5 [11701933.001]
  • [Cites] Bioconjug Chem. 2002 Jan-Feb;13(1):40-6 [11792177.001]
  • [Cites] Biochem J. 2002 May 1;363(Pt 3):417-29 [11964142.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2546-53 [11980648.001]
  • [Cites] EMBO J. 2002 Aug 1;21(15):3989-4000 [12145200.001]
  • [Cites] Oncology. 2002;63 Suppl 1:17-24 [12422051.001]
  • [Cites] Crit Care Nurse. 2002 Dec;22(6):52-60 [12518568.001]
  • [Cites] Nat Biotechnol. 2003 Jul;21(7):778-84 [12778055.001]
  • [Cites] Anal Biochem. 2003 Sep 1;320(1):13-20 [12895465.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):13044-53 [14722062.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22284-93 [14985369.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6607-14 [15153475.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4629-36 [15231675.001]
  • [Cites] Biochim Biophys Acta. 1978 Jan 18;538(2):343-53 [339961.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jan;79(2):626-9 [6952214.001]
  • [Cites] J Gen Virol. 1982 Jan;58 Pt 1:47-61 [7142969.001]
  • [Cites] Biochem J. 1984 Mar 15;218(3):775-83 [6721834.001]
  • [Cites] J Biol Chem. 1985 Sep 15;260(20):10905-8 [4030773.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] J Natl Cancer Inst. 1987 Nov;79(5):1163-72 [3500356.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2639-48 [10561337.001]
  • [Cites] Semin Cell Dev Biol. 1999 Oct;10(5):481-93 [10597631.001]
  • [Cites] Nature. 1988 May 5;333(6168):90-3 [3129663.001]
  • [Cites] Cancer Res. 1988 Nov 15;48(22):6396-403 [3263186.001]
  • [Cites] J Cell Biol. 1990 Feb;110(2):327-35 [2404990.001]
  • [Cites] J Biol Chem. 1990 Aug 15;265(23):13533-9 [2380172.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):211-22 [12525512.001]
  • [Cites] J Biol Chem. 1990 Nov 5;265(31):18780-5 [2229041.001]
  • [Cites] Cancer Immunol Immunother. 1991;33(6):367-74 [1878890.001]
  • [Cites] J Exp Med. 1991 Nov 1;174(5):1121-30 [1940793.001]
  • [Cites] Cancer Res. 1992 Jan 1;52(1):127-31 [1727373.001]
  • [Cites] J Immunol. 1991 Dec 15;147(12):4054-9 [1721638.001]
  • [Cites] Experientia. 1992 Feb 15;48(2):151-7 [1740187.001]
  • [Cites] Science. 1992 Sep 11;257(5076):1496-502 [1523409.001]
  • [Cites] J Biol Chem. 1993 Jan 25;268(3):1567-74 [8420931.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):4112-6 [8387210.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4684-90 [8062265.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8618-23 [8710920.001]
  • [Cites] Semin Immunol. 1995 Dec;7(6):347-53 [8775460.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:575-625 [8970738.001]
  • [Cites] FEBS Lett. 1997 Jan 20;401(2-3):104-8 [9013867.001]
  • [Cites] J Biol Chem. 1997 Nov 21;272(47):29399-402 [9367991.001]
  • [Cites] Genes Dev. 1999 May 15;13(10):1211-33 [10346810.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7995-8001 [15520207.001]
  • [Cites] Mol Biol Cell. 2004 Dec;15(12):5268-82 [15385631.001]
  • [Cites] Curr Opin Mol Ther. 2004 Dec;6(6):666-74 [15663331.001]
  • [Cites] J Med Chem. 2005 Mar 10;48(5):1344-58 [15743178.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Curr Opin Pharmacol. 2005 Aug;5(4):382-7 [15951239.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):25907-14 [10852914.001]
  • (PMID = 16322102.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Benzoquinones; 0 / Disulfides; 0 / Immunoconjugates; 0 / Lactams, Macrocyclic; 0 / Quinones; 0 / Rhodamines; 147336-22-9 / Green Fluorescent Proteins; P188ANX8CK / Trastuzumab; Z3K3VJ16KU / geldanamycin
  • [Other-IDs] NLM/ PMC1298180
  •  go-up   go-down


47. Tang J, Kan ZY, Yao Y, Wang Q, Hao YH, Tan Z: G-quadruplex preferentially forms at the very 3' end of vertebrate telomeric DNA. Nucleic Acids Res; 2008 Mar;36(4):1200-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This shortening in most tumor cells is compensated by telomerase that adds telomere repeats to the 3' end of the G-rich telomere strand.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Pharmacol Sci. 2000 Apr;21(4):136-42 [10740289.001]
  • [Cites] Cell. 1997 Mar 7;88(5):657-66 [9054505.001]
  • [Cites] Biol Chem. 2001 Apr;382(4):621-8 [11405224.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8572-7 [11438689.001]
  • [Cites] Mol Pharmacol. 2001 Nov;60(5):981-8 [11641426.001]
  • [Cites] Genes Dev. 1997 Nov 1;11(21):2801-9 [9353250.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27587-92 [9765292.001]
  • [Cites] Biochemistry. 1998 Nov 17;37(46):16325-37 [9819225.001]
  • [Cites] Nucleic Acids Res. 1999 Jan 15;27(2):537-42 [9862977.001]
  • [Cites] J Biol Chem. 1999 Apr 30;274(18):12797-802 [10212265.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):598-610 [11850785.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2672-7 [11854467.001]
  • [Cites] Nat Rev Drug Discov. 2002 May;1(5):383-93 [12120414.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11593-8 [12195017.001]
  • [Cites] Mini Rev Med Chem. 2001 May;1(1):31-41 [12369989.001]
  • [Cites] Nucleic Acids Res. 2002 Nov 1;30(21):4618-25 [12409451.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1569-73 [12574521.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3247-56 [12810655.001]
  • [Cites] Curr Med Res Opin. 2003;19(6):470-2 [14594517.001]
  • [Cites] Angew Chem Int Ed Engl. 2003 Dec 1;42(46):5734-6 [14661209.001]
  • [Cites] Cell. 1999 May 14;97(4):503-14 [10338214.001]
  • [Cites] J Biol Chem. 2004 Dec 17;279(51):53770-81 [15456773.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1489-96 [15735037.001]
  • [Cites] Mol Cell. 2005 Apr 1;18(1):131-8 [15808515.001]
  • [Cites] Oncogene. 2005 Apr 21;24(18):2917-28 [15735722.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18862-70 [15734733.001]
  • [Cites] Trends Biochem Sci. 2005 Jul;30(7):388-95 [15936947.001]
  • [Cites] Nucleic Acids Res. 2005;33(13):4182-90 [16052031.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10864-9 [16043710.001]
  • [Cites] Curr Pharm Des. 2005;11(22):2841-54 [16101441.001]
  • [Cites] Nat Struct Mol Biol. 2005 Oct;12(10):847-54 [16142245.001]
  • [Cites] Nucleic Acids Res. 2005;33(18):5851-60 [16221978.001]
  • [Cites] Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R191-6 [16244317.001]
  • [Cites] Anal Chem. 2006 Mar 1;78(5):1478-84 [16503597.001]
  • [Cites] Oncogene. 2006 Mar 23;25(13):1955-66 [16302000.001]
  • [Cites] Anal Chem. 2006 Apr 15;78(8):2810-5 [16615797.001]
  • [Cites] J Am Chem Soc. 2006 Apr 26;128(16):5404-15 [16620112.001]
  • [Cites] Bioorg Med Chem Lett. 2006 Aug 1;16(15):3891-5 [16735121.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6908-12 [16849533.001]
  • [Cites] Org Biomol Chem. 2006 Sep 21;4(18):3383-91 [17036128.001]
  • [Cites] Nucleic Acids Res. 2006;34(17):4857-65 [16973897.001]
  • [Cites] J Am Chem Soc. 2006 Dec 6;128(48):15461-8 [17132013.001]
  • [Cites] J Biol Chem. 2006 Dec 15;281(50):38721-9 [17050546.001]
  • [Cites] Br J Cancer. 2007 Apr 23;96(8):1223-33 [17406367.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Apr;5(4):323-9 [15071557.001]
  • [Cites] Cell. 2004 Jun 25;117(7):873-86 [15210109.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1618-29 [15231739.001]
  • [Cites] Anal Chem. 2004 Aug 1;76(15):4490-4 [15283592.001]
  • [Cites] J Am Chem Soc. 2004 Oct 20;126(41):13255-64 [15479079.001]
  • [Cites] J Biol Chem. 1972 May 25;247(10):3139-46 [4554914.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Feb;74(2):560-4 [265521.001]
  • [Cites] Nature. 1988 Jul 28;334(6180):364-6 [3393228.001]
  • [Cites] Nature. 1991 Apr 18;350(6319):569-73 [1708110.001]
  • [Cites] Nature. 1991 Apr 25;350(6320):718-20 [2023635.001]
  • [Cites] Biochemistry. 1993 Apr 13;32(14):3596-603 [8466901.001]
  • [Cites] J Biol Chem. 1994 Aug 26;269(34):21858-69 [8063830.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Nucleic Acids Symp Ser. 1995;(33):134-6 [8643349.001]
  • [Cites] Nucleic Acids Res. 1997 Jan 15;25(2):297-303 [9016557.001]
  • [Cites] Science. 2001 May 11;292(5519):1171-5 [11349150.001]
  • (PMID = 18158301.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9007-49-2 / DNA; EC 3.1.- / Exodeoxyribonucleases
  • [Other-IDs] NLM/ PMC2275102
  •  go-up   go-down


48. Shangguan D, Meng L, Cao ZC, Xiao Z, Fang X, Li Y, Cardona D, Witek RP, Liu C, Tan W: Identification of liver cancer-specific aptamers using whole live cells. Anal Chem; 2008 Feb 1;80(3):721-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, accurate early diagnosis would significantly improve the clinical outcome of liver cancer.
  • The objective of our current study is to identify liver cancer cell-specific molecular probes that could be used for liver cancer recognition and diagnosis.
  • The first one is that our current study demonstrates that cell-based aptamer selection can select specific aptamers for multiple cell lines, even for two cell lines with minor differences (MEAR cell is derived from BNL by chemical inducement); and the second result is that cell-SELEX can be used for adhesive cells and thus open the door for solid tumor selection and investigation.
  • The newly generated cancer-specific aptamers hold great promise as molecular probes for cancer early diagnosis and basic mechanism studies.
  • [MeSH-major] Aptamers, Nucleotide / genetics. Liver Neoplasms / pathology. SELEX Aptamer Technique / methods
  • [MeSH-minor] Animals. Base Sequence. Binding Sites. Cell Differentiation / genetics. Cell Differentiation / physiology. Cell Line, Tumor. DNA / genetics. DNA / metabolism. Mice. Mice, Inbred BALB C. Molecular Sequence Data. RNA / genetics. RNA / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18177018.001).
  • [ISSN] 0003-2700
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK02958; United States / NIGMS NIH HHS / GM / R01 GM079359; United States / NINDS NIH HHS / NS / U54 NS 058185
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aptamers, Nucleotide; 63231-63-0 / RNA; 9007-49-2 / DNA
  •  go-up   go-down


49. Sasaki A, Sugita S, Horimi K, Yasuda K, Inomata M, Kitano S: Retrorectal epidermoid cyst in an elderly woman: report of a case. Surg Today; 2008;38(8):761-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mass was exposed after an excision of subcutaneous fat and was firmly adhered to the anal sphincter muscle.
  • A diagnosis of retrorectal cystic tumor is difficult, and a complete resection is necessary for the treatment of such tumors.

  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1994;24(6):556-60 [7919742.001]
  • [Cites] Radiographics. 2001 May-Jun;21(3):575-84 [11353107.001]
  • [Cites] Surg Gynecol Obstet. 1962 Oct;115:449-52 [13915701.001]
  • [Cites] Am Surg. 1994 Apr;60(4):267-72 [8129248.001]
  • [Cites] Hepatogastroenterology. 1996 Sep-Oct;43(11):1399-402 [8908582.001]
  • [Cites] Diagn Cytopathol. 2000 Jun;22(6):376-8 [10820532.001]
  • [Cites] Am J Clin Pathol. 1988 Feb;89(2):139-47 [3277378.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):880-6 [12788424.001]
  • [Cites] Ann Surg. 1964 Jun;159:911-8 [14170292.001]
  • [Cites] Ann Ital Chir. 2006 Jan-Feb;77(1):75-7 [16910365.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):644-52 [2996861.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1581-7 [15937630.001]
  • [Cites] Chir Ital. 2002 Jul-Aug;54(4):545-8 [12239766.001]
  • [Cites] Diagn Cytopathol. 1990;6(5):359-63 [2292221.001]
  • (PMID = 18668324.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Atkinson DM, Clarke MJ, Mladek AC, Carlson BL, Trump DP, Jacobson MS, Kemp BJ, Lowe VJ, Sarkaria JN: Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts. Head Neck; 2008 Jun;30(6):790-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: 3'-18F-fluoro-3'-deoxy-fluorothymidine (18F-FLT), a nucleoside analog, could monitor effects of molecularly targeted therapeutics on tumor proliferation.
  • FLT uptake suppression following anti-epidermal growth factor receptor (EGFR) treatment was associated with reduced tumor thymidine kinase-1 (TK1) activity.
  • CONCLUSIONS: 18F-FLT PET imaging detects tumor responses to EGFR-inhibitors within days of starting therapy.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2166-74 [10873065.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8558-64 [16951168.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3331-4 [12067968.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1210-7 [12215561.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1462-9 [12397465.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3315-23 [12429617.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2681-7 [12750297.001]
  • [Cites] Gut. 2003 Nov;52(11):1602-6 [14570730.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12):2027-32 [14660729.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):695-700 [15073267.001]
  • [Cites] Cell Res. 2004 Aug;14(4):295-302 [15353126.001]
  • [Cites] Acta Biol Med Ger. 1972;29(4):483-94 [4347226.001]
  • [Cites] J Biol Chem. 1991 May 15;266(14):9032-8 [2026611.001]
  • [Cites] Biochem Pharmacol. 1992 Jul 22;44(2):199-204 [1322661.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1334-6 [9809561.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):114-20 [15632041.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3003-10 [15833824.001]
  • [Cites] Anal Cell Pathol. 2001;23(1):11-9 [11790855.001]
  • (PMID = 18286491.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108961; United States / NCI NIH HHS / CA / R21 CA104310; United States / NCI NIH HHS / CA / CA0108961; United States / NCI NIH HHS / CA / CA104310; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / U10 CA025224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Dideoxynucleosides; 0 / Fluorine Radioisotopes; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PG53R0DWDQ / alovudine; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ NIHMS548870; NLM/ PMC3942889
  •  go-up   go-down


51. Dhar SK, Xu Y, Noel T, St Clair DK: Chronic exposure to 12-O-tetradecanoylphorbol-13-acetate represses sod2 induction in vivo: the negative role of p50. Carcinogenesis; 2007 Dec;28(12):2605-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is well documented that the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) can activate manganese superoxide dismutase (MnSOD) expression.
  • However, it is unclear how repeated exposure to TPA following a single application of tumor initiator 7,12-dimethylbenz-(a)-anthracene causes tumor development.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28209-19 [15087454.001]
  • [Cites] FASEB J. 2005 Apr;19(6):650-2 [15659537.001]
  • [Cites] Cancer Res. 1979 Apr;39(4):1141-9 [217531.001]
  • [Cites] Nature. 1984 Apr 19-25;308(5961):693-8 [6232463.001]
  • [Cites] EMBO J. 1986 Mar;5(3):623-30 [3011417.001]
  • [Cites] Mech Ageing Dev. 1989 Apr;48(1):15-31 [2542703.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):8-18 [2547324.001]
  • [Cites] J Biol Chem. 1991 Jan 5;266(1):252-60 [1985897.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):939-43 [1988135.001]
  • [Cites] Free Radic Res Commun. 1991;12-13 Pt 2:751-7 [2060847.001]
  • [Cites] Nucleic Acids Res. 1991 Aug 11;19(15):4293 [1870982.001]
  • [Cites] Genes Dev. 1991 Sep;5(9):1646-56 [1885006.001]
  • [Cites] Endocrinology. 1991 Nov;129(5):2376-84 [1718727.001]
  • [Cites] J Biol Chem. 1991 Dec 5;266(34):23142-6 [1744113.001]
  • [Cites] J Biol Chem. 1992 Nov 25;267(33):23937-41 [1385428.001]
  • [Cites] Blood. 1993 Feb 1;81(3):639-46 [8427959.001]
  • [Cites] Int Rev Cytol. 1993;143:1-62 [8449662.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7 [8464931.001]
  • [Cites] Carcinogenesis. 1993 Jul;14(7):1457-63 [8330364.001]
  • [Cites] Am J Physiol. 1993 Oct;265(4 Pt 2):H1173-8 [8238402.001]
  • [Cites] Am J Respir Cell Mol Biol. 1994 Jan;10(1):113-21 [8292376.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4261-5 [8044768.001]
  • [Cites] Adv Exp Med Biol. 1995;369:167-74 [7598004.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):376-81 [7493016.001]
  • [Cites] Free Radic Biol Med. 1995 Dec;19(6):823-35 [8582655.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2864-71 [8665527.001]
  • [Cites] J Clin Invest. 1996 Sep 1;98(5):1253-60 [8787689.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):481-90 [9053845.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):6970-81 [9372929.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1554-9 [16261162.001]
  • [Cites] J Biol Chem. 2006 Aug 4;281(31):21698-709 [16740634.001]
  • [Cites] DNA Cell Biol. 1994 Nov;13(11):1127-36 [7702755.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2490-3 [7780953.001]
  • [Cites] J Biol Chem. 1995 Jun 30;270(26):15864-9 [7797591.001]
  • [Cites] J Biol Chem. 2001 Apr 27;276(17):14407-13 [11278550.001]
  • [Cites] Biochim Biophys Acta. 2001 May 3;1526(2):191-8 [11325541.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6082-8 [11507057.001]
  • [Cites] DNA Cell Biol. 2001 Aug;20(8):473-81 [11560779.001]
  • [Cites] Biochem J. 2002 Mar 1;362(Pt 2):401-12 [11853549.001]
  • [Cites] Mol Cell. 2002 Mar;9(3):625-36 [11931769.001]
  • [Cites] Methods Mol Biol. 2003;218:177-84 [12616721.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):8460-8 [14668329.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5265-71 [9393747.001]
  • [Cites] J Neurosci. 1998 Jan 15;18(2):687-97 [9425011.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Jan;284(1):215-21 [9435181.001]
  • [Cites] Nat Genet. 1998 Feb;18(2):159-63 [9462746.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1266-74 [9488441.001]
  • [Cites] DNA Cell Biol. 1999 Sep;18(9):709-22 [10492402.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1401-5 [15735027.001]
  • [Cites] Science. 1978 Sep 8;201(4359):875-80 [210504.001]
  • (PMID = 17652337.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 73599; United States / NCI NIH HHS / CA / CA073599-09A1; United States / NCI NIH HHS / CA / CA049797-17; United States / NCI NIH HHS / CA / R01 CA073599; United States / NCI NIH HHS / CA / CA 49797; United States / NCI NIH HHS / CA / R01 CA073599-09A1; United States / NCI NIH HHS / CA / R01 CA049797; United States / NCI NIH HHS / CA / R01 CA049797-17
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B p50 Subunit; 0 / Nuclear Proteins; 0 / Sp1 Transcription Factor; 0 / Transcription Factor RelA; 117896-08-9 / nucleophosmin; EC 1.13.12.- / Luciferases; EC 1.15.1.1 / Superoxide Dismutase; EC 1.15.1.1 / superoxide dismutase 2; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS86977; NLM/ PMC2656647
  •  go-up   go-down


52. Rolls A, Shechter R, London A, Segev Y, Jacob-Hirsch J, Amariglio N, Rechavi G, Schwartz M: Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. PLoS Med; 2008 Aug 19;5(8):e171
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Yet, the abundant de novo synthesis of CSPG in response to CNS injury is puzzling.
  • Using the chimeric mice we found that the immediate inhibition of CSPG production caused a dramatic effect on the spatial organization of the infiltrating myeloid cells around the lesion site, decreased insulin-like growth factor 1 (IGF-1) production by microglia/macrophages, and increased tumor necrosis factor alpha (TNF-alpha) levels.

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Neurosci. 2007 Jan;8(1):57-69 [17180163.001]
  • [Cites] Mol Neurobiol. 2006 Dec;34(3):221-42 [17308354.001]
  • [Cites] Glia. 2002 Jul;39(1):85-97 [12112378.001]
  • [Cites] J Neurosci. 2002 Sep 1;22(17):7526-35 [12196576.001]
  • [Cites] J Neurol Sci. 2002 Oct 15;202(1-2):13-23 [12220687.001]
  • [Cites] Brain. 2007 Apr;130(Pt 4):940-53 [17314203.001]
  • [Cites] Brain Res. 2007 Jul 23;1159:8-17 [17572395.001]
  • [Cites] Neuroscience. 2007 Jul 29;147(4):867-83 [17459594.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2277-82 [17540856.001]
  • [Cites] Nat Neurosci. 2007 Dec;10(12):1544-53 [18026096.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):4106-14 [10805752.001]
  • [Cites] Curr Opin Neurobiol. 2001 Feb;11(1):89-94 [11179877.001]
  • [Cites] J Neurosci Res. 2001 Jan 1;63(1):90-7 [11169618.001]
  • [Cites] Neurobiol Dis. 2001 Feb;8(1):11-8 [11162236.001]
  • [Cites] Brain Res. 2001 Mar 2;893(1-2):104-12 [11222998.001]
  • [Cites] J Cereb Blood Flow Metab. 2001 Jul;21(7):828-34 [11435795.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jul;60(7):676-85 [11444796.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Dec;60(12):1198-207 [11764092.001]
  • [Cites] J Neurosci. 2002 Apr 1;22(7):2792-803 [11923444.001]
  • [Cites] Nature. 2002 Apr 11;416(6881):636-40 [11948352.001]
  • [Cites] Restor Neurol Neurosci. 2001;19(3-4):189-98 [12082221.001]
  • [Cites] J Neuroimmunol. 2003 Jan;134(1-2):25-34 [12507769.001]
  • [Cites] Glia. 2003 Apr 1;42(1):36-45 [12594735.001]
  • [Cites] Biochem Soc Trans. 2003 Apr;31(2):335-6 [12653631.001]
  • [Cites] J Neurosci. 2003 Mar 15;23(6):2284-93 [12657687.001]
  • [Cites] Brain Res Dev Brain Res. 2003 May 14;142(2):111-9 [12711362.001]
  • [Cites] Mol Neurobiol. 2003 Apr;27(2):153-62 [12777685.001]
  • [Cites] Trends Neurosci. 2003 Oct;26(10):555-63 [14522149.001]
  • [Cites] Nat Rev Neurosci. 2004 Feb;5(2):146-56 [14735117.001]
  • [Cites] J Neurosci. 2004 Mar 3;24(9):2143-55 [14999065.001]
  • [Cites] J Neurosci. 2004 Mar 3;24(9):2182-90 [14999069.001]
  • [Cites] Neurobiol Aging. 2004 May-Jun;25(5):663-74 [15172746.001]
  • [Cites] Aging Cell. 2004 Aug;3(4):169-76 [15268750.001]
  • [Cites] Eur J Neurosci. 2004 Oct;20(8):1973-83 [15450076.001]
  • [Cites] J Dent Res. 2004 Nov;83(11):880-5 [15505240.001]
  • [Cites] Anal Biochem. 1982 Oct;126(1):131-8 [7181105.001]
  • [Cites] Neuron. 1990 Oct;5(4):463-9 [2206534.001]
  • [Cites] Adv Exp Med Biol. 1992;313:329-40 [1442268.001]
  • [Cites] J Clin Invest. 1993 Jun;91(6):2368-77 [8514850.001]
  • [Cites] Nature. 1994 Nov 10;372(6502):182-6 [7969452.001]
  • [Cites] Nature. 1995 Apr 13;374(6523):647-50 [7715705.001]
  • [Cites] Exp Neurol. 1996 Nov;142(1):103-10 [8912902.001]
  • [Cites] J Neurosci Methods. 1997 Mar;72(1):57-63 [9128169.001]
  • [Cites] Endocrinology. 1997 Jul;138(7):3024-34 [9202248.001]
  • [Cites] Exp Neurol. 1997 Dec;148(2):587-603 [9417835.001]
  • [Cites] J Neurobiol. 1998 Jan;34(1):41-54 [9469617.001]
  • [Cites] Nat Med. 1998 Jul;4(7):814-21 [9662373.001]
  • [Cites] J Immunol. 1998 Sep 1;161(5):2465-72 [9725245.001]
  • [Cites] Nat Med. 1999 Jan;5(1):49-55 [9883839.001]
  • [Cites] Exp Neurol. 1999 Aug;158(2):351-65 [10415142.001]
  • [Cites] Metab Brain Dis. 2004 Dec;19(3-4):393-411 [15554430.001]
  • [Cites] Congenit Anom (Kyoto). 2004 Dec;44(4):181-8 [15566408.001]
  • [Cites] Int Immunopharmacol. 2005 Jan;5(1):185-93 [15589480.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11961-72 [15655247.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Apr;48(2):234-9 [15850662.001]
  • [Cites] J Exp Med. 2005 Jul 4;202(1):145-56 [15998793.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3114-22 [16020513.001]
  • [Cites] Mol Cell Neurosci. 2006 Jan;31(1):149-60 [16297637.001]
  • [Cites] J Neurosci. 2006 Feb 8;26(6):1730-8 [16467521.001]
  • [Cites] Mol Psychiatry. 2006 Apr;11(4):327-35 [16491130.001]
  • [Cites] FASEB J. 2006 Apr;20(6):714-6 [16473887.001]
  • [Cites] J Neurotrauma. 2006 May;23(5):635-59 [16689667.001]
  • [Cites] Nat Med. 2006 Jul;12(7):829-34 [16783372.001]
  • [Cites] J Neurosci. 2006 Sep 27;26(39):9841-50 [17005848.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):16021-6 [17043238.001]
  • [Cites] J Neurochem. 2006 Nov;99(4):1176-87 [17018025.001]
  • [Cites] Nat Neurosci. 2006 Dec;9(12):1463-4 [17128280.001]
  • [Cites] Brain. 2006 Dec;129(Pt 12):3249-69 [17071951.001]
  • [Cites] Glia. 2007 Feb;55(3):294-302 [17096403.001]
  • (PMID = 18715114.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Chondroitin Sulfate Proteoglycans; 0 / Nerve Growth Factors; 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ PMC2517615
  •  go-up   go-down


53. Johnson RD, Navratil M, Poe BG, Xiong G, Olson KJ, Ahmadzadeh H, Andreyev D, Duffy CF, Arriaga EA: Analysis of mitochondria isolated from single cells. Anal Bioanal Chem; 2007 Jan;387(1):107-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bulk studies are not suitable to describe and study cell-to-cell variation, which is of high importance in biological processes such as embryogenesis, tissue differentiation, and disease.
  • Osteosarcoma 143B cells are labeled with either the fluorescent mitochondrion-specific 10-N-nonyl acridine orange (NAO) or via expression of the fluorescent protein DsRed2.
  • From an electropherogram, the number of detected events per cell, their individual electrophoretic mobilities, and their individual fluorescence intensities are calculated.
  • The results obtained from DsRed2 labeling, which is retained in intact mitochondria, and NAO labeling, which labels all mitochondria, are the basis for discussion of the strengths and limitations of this single-cell approach.
  • [MeSH-minor] Acridine Orange / analogs & derivatives. Acridine Orange / analysis. Acridine Orange / chemistry. Cell Line, Tumor. Cell Membrane / drug effects. Cell Membrane / metabolism. Cytoskeletal Proteins / metabolism. Cytoskeleton / drug effects. Cytoskeleton / metabolism. Digitonin / chemistry. Digitonin / pharmacology. Fluorescent Dyes / analysis. Fluorescent Dyes / chemistry. Humans. Lasers. Luminescent Proteins / analysis. Luminescent Proteins / genetics. Trypsin / metabolism. Trypsin / pharmacology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16937092.001).
  • [ISSN] 1618-2642
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG20866; United States / NIGMS NIH HHS / GM / GM08347; United States / NIA NIH HHS / AG / K02-AG21453
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / Fluorescent Dyes; 0 / Luminescent Proteins; 0 / fluorescent protein 583; 78125-98-1 / N(10)-nonylacridine orange; EC 3.4.21.4 / Trypsin; F30N4O6XVV / Acridine Orange; KOO5CM684H / Digitonin
  •  go-up   go-down


54. Zielonka J, Kalyanaraman B: "ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis"--a critical commentary. Free Radic Biol Med; 2008 Nov 1;45(9):1217-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis"--a critical commentary.
  • Ishikawa et al., 2008, Science320, 661-664), the authors described how replacing the endogenous mitochondrial DNA (mtDNA) in a weakly metastatic mouse tumor cell line with mtDNA from a highly metastatic cell line enhanced tumor progression through enhanced production of reactive oxygen species (ROS).
  • The authors attributed the transformation from a low-metastatic cell line to a high-metastatic phenotype to overproduction of ROS (hydrogen peroxide and superoxide) caused by a dysfunction in mitochondrial complex I protein encoded by mtDNA transferred from the highly metastatic tumor cell line.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 23;282(1):329-33 [11264011.001]
  • [Cites] Science. 2008 May 2;320(5876):661-4 [18388260.001]
  • [Cites] Circ Res. 2003 Jan 10;92(1):56-63 [12522121.001]
  • [Cites] Free Radic Biol Med. 2003 Jun 1;34(11):1359-68 [12757846.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29410-9 [12748170.001]
  • [Cites] Anal Biochem. 2004 Sep 15;332(2):290-8 [15325298.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Oct;287(4):C895-902 [15306539.001]
  • [Cites] Chem Res Toxicol. 1992 Mar-Apr;5(2):227-31 [1322737.001]
  • [Cites] Free Radic Biol Med. 1999 Jan;26(1-2):148-61 [9890650.001]
  • [Cites] J Biol Chem. 1999 Oct 1;274(40):28161-8 [10497168.001]
  • [Cites] Free Radic Biol Med. 1999 Oct;27(7-8):873-81 [10515592.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 15;38(2):262-70 [15607909.001]
  • [Cites] Anal Bioanal Chem. 2005 Mar;381(5):1065-72 [15690180.001]
  • [Cites] Biochem Soc Symp. 2004;(71):97-106 [15777015.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5727-32 [15824309.001]
  • [Cites] Free Radic Biol Med. 2005 Oct 1;39(7):853-63 [16140206.001]
  • [Cites] Free Radic Biol Med. 2006 Mar 15;40(6):968-75 [16540392.001]
  • [Cites] Free Radic Biol Med. 2006 Aug 15;41(4):657-67 [16863999.001]
  • [Cites] Free Radic Biol Med. 2006 Oct 1;41(7):1050-7 [16962930.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15038-43 [17015830.001]
  • [Cites] Arch Biochem Biophys. 2006 Dec 1;456(1):39-47 [17081495.001]
  • [Cites] Free Radic Biol Med. 2007 Oct 1;43(7):995-1022 [17761297.001]
  • [Cites] Free Radic Biol Med. 2008 Jan 1;44(1):56-62 [18045547.001]
  • [Cites] Nat Protoc. 2008;3(1):8-21 [18193017.001]
  • [Cites] Free Radic Biol Med. 2008 Mar 1;44(5):835-46 [18155177.001]
  • [Cites] FEBS Lett. 2002 Jan 30;511(1-3):21-7 [11821042.001]
  • (PMID = 18789385.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL073056; United States / NINDS NIH HHS / NS / NS039958; United States / NINDS NIH HHS / NS / R01 NS039958; United States / NHLBI NIH HHS / HL / HL073056; United States / NHLBI NIH HHS / HL / R01HL067244; United States / NHLBI NIH HHS / HL / R01 HL067244
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-(6'-triphenylphosphoniumhexyl)-5,6-dihydro-6-phenyl-3,8-phenanthridinediammine; 0 / DNA, Mitochondrial; 0 / DNA, Neoplasm; 0 / Fluorescent Dyes; 0 / Phenanthridines; 0 / Reactive Oxygen Species; 11062-77-4 / Superoxides; 38483-26-0 / hydroethidine; BBX060AN9V / Hydrogen Peroxide
  • [Other-IDs] NLM/ NIHMS76248; NLM/ PMC3595710
  •  go-up   go-down


55. Boonnuch W, Lohsiriwat V, Akaraviputh T, Chinswangwatanakul V, Lohsiriwat D: The surgical outcome of preoperative chemoradiation therapy for ultra low rectal cancer. J Med Assoc Thai; 2009 Nov;92(11):1423-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHOD: Medical records of patients with rectal adenocarcinoma located within the length of 5 cm from the anal verge, who underwent elective oncological resection between 2003 and 2006 at Siriraj Hospital, were reviewed.
  • PCRT was performed in some patients based on tumor characteristics and surgeon's decision.
  • There was no difference in demographic data and location of the tumor between PCRT and non-PCRT group.
  • Patients with PCRT had a smaller size of tumor (2.6 vs. 5.0 cm, p < 0.001) and better tumor staging (p < 0.001).
  • [MeSH-major] Anal Canal / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19938732.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


56. Hanin L, Yakovlev A: Identifiability of the joint distribution of age and tumor size at detection in the presence of screening. Math Biosci; 2007 Aug;208(2):644-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identifiability of the joint distribution of age and tumor size at detection in the presence of screening.
  • The model is entirely mechanistic, builds on a minimal set of biologically plausible assumptions, and yields the joint distribution of tumor size and age of a patient at the time of diagnosis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 1995 Jul 30;14(14):1531-43 [7481190.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3547-51 [8490903.001]
  • [Cites] Radiat Environ Biophys. 1996 May;35(2):127-9 [8792461.001]
  • [Cites] Risk Anal. 1996 Oct;16(5):711-5 [8962520.001]
  • [Cites] Risk Anal. 1997 Jun;17(3):391-9 [9232020.001]
  • [Cites] Biometrics. 1997 Dec;53(4):1495-502 [9423264.001]
  • [Cites] Stat Methods Med Res. 2004 Dec;13(6):457-89 [15587434.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1784-92 [16251534.001]
  • [Cites] J Natl Cancer Inst Monogr. 2006;(36):66-78 [17032896.001]
  • [Cites] Biometrics. 1995 Jun;51(2):437-47 [7662836.001]
  • [Cites] Math Biosci. 2001 Jun;171(2):113-42 [11395047.001]
  • [Cites] Biometrics. 2001 Jun;57(2):389-95 [11414561.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3490-9 [11481355.001]
  • [Cites] Math Biosci. 2002 Jan;175(1):13-29 [11779625.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):835-42 [14623621.001]
  • [Cites] Biometrics. 1969 Mar;25(1):95-109 [5786312.001]
  • [Cites] Cancer. 1978 Apr;41(4):1550-64 [639011.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1037-52 [6941039.001]
  • [Cites] Am J Epidemiol. 1983 Dec;118(6):865-86 [6650488.001]
  • [Cites] Biometrics. 1984 Mar;40(1):1-14 [6733223.001]
  • [Cites] Biometrics. 1987 Sep;43(3):657-69 [3663822.001]
  • [Cites] Risk Anal. 1990 Jun;10(2):323-41 [2195604.001]
  • [Cites] Int J Cancer. 1990 Aug 15;46(2):207-13 [2384271.001]
  • [Cites] Math Biosci. 1991 Nov;107(1):21-45 [1806106.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6671-5 [8692876.001]
  • (PMID = 17303192.001).
  • [ISSN] 0025-5564
  • [Journal-full-title] Mathematical biosciences
  • [ISO-abbreviation] Math Biosci
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA088177-02; United States / NCI NIH HHS / CA / U01 CA088177-01; United States / NCI NIH HHS / CA / U01 CA088177; United States / NCI NIH HHS / CA / U01 CA088177-05; United States / NCI NIH HHS / CA / CA088177-04; United States / NCI NIH HHS / CA / U01 CA88177; United States / NCI NIH HHS / CA / CA088177-05; United States / NCI NIH HHS / CA / CA088177-02; United States / NCI NIH HHS / CA / CA088177-01; United States / NCI NIH HHS / CA / CA088177-03; United States / NCI NIH HHS / CA / U01 CA088177-03; United States / NCI NIH HHS / CA / U01 CA088177-05S1; United States / NCI NIH HHS / CA / CA088177-05S1; United States / NCI NIH HHS / CA / U01 CA088177-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS28695; NLM/ PMC2041843
  •  go-up   go-down


57. Antillon MR, Bartalos CR, Miller ML, Diaz-Arias AA, Ibdah JA, Marshall JB: En bloc endoscopic submucosal dissection of a 14-cm laterally spreading adenoma of the rectum with involvement to the anal canal: expanding the frontiers of endoscopic surgery (with video). Gastrointest Endosc; 2008 Feb;67(2):332-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] En bloc endoscopic submucosal dissection of a 14-cm laterally spreading adenoma of the rectum with involvement to the anal canal: expanding the frontiers of endoscopic surgery (with video).
  • BACKGROUND: Endoscopic submucosal dissection (ESD) was recently developed in Japan for en bloc removal of laterally spreading tumors (LSTs).
  • Although initially used for gastric tumors, ESD has now been applied to lesions elsewhere in the gut.
  • The tumor extended distally to the dentate line.
  • INTERVENTIONS: En bloc submucosal dissection with a conventional needle-knife to remove the neoplasm.
  • MAIN OUTCOME MEASUREMENTS: Completeness of en bloc removal of the tumor and subsequent follow-up endoscopy that showed no residual neoplasm.
  • RESULTS: The tumor was able to be removed en bloc by ESD.
  • At the time of the last follow-up, there was complete healing of the wound and no residual neoplasm.
  • CONCLUSIONS: This case demonstrated the feasibility of using ESD to remove large laterally spreading rectal tumors, including when there was involvement to the dentate line (and the dissection line must include squamous mucosa of the anal canal).
  • [MeSH-major] Adenoma / surgery. Anal Canal / pathology. Electrocoagulation / methods. Rectal Neoplasms / surgery. Thoracoscopy / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18226698.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Song H, Chen T, Zhang B, Ma Y, Wang Z: An integrated microfluidic cell array for apoptosis and proliferation analysis induction of breast cancer cells. Biomicrofluidics; 2010;4(4):44104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro sensitivity testing of tumor cells could rationalize and improve the choice of chemotherapy and hormone therapy.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042433.001).
  • [ISSN] 1932-1058
  • [Journal-full-title] Biomicrofluidics
  • [ISO-abbreviation] Biomicrofluidics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2966486
  •  go-up   go-down


59. Poola I, Abraham J, Liu A, Marshalleck JJ, Dewitty RL: The Cell Surface Estrogen Receptor, G Protein- Coupled Receptor 30 (GPR30), is Markedly Down Regulated During Breast Tumorigenesis. Breast Cancer (Auckl); 2008;1:65-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: To understand the role of GPR30 in the deregulation of estrogen signaling processes during breast carcinogenesis, we have undertaken this study to investigate its expression at mRNA levels in tumor tissues and their matched normal tissues.
  • The GPR30 expression levels were significantly lower in tumor tissues from patients (n = 29) who had lymph node metastasis in comparison with tumors from patients (n = 53) who were negative for lymph node metastasis (two sample t-test, p < 0.02), but no association was found with ERα, PR and other tumor characteristics.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2005 Mar 11;307(5715):1625-30 [15705806.001]
  • [Cites] Endocrinology. 1997 Sep;138(9):4030-3 [9275096.001]
  • [Cites] Mol Endocrinol. 2006 Mar;20(3):631-46 [16239258.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7579-85 [16243834.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Aug 4;346(3):904-10 [16780796.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1859-66 [17308128.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8517-21 [8078914.001]
  • [Cites] Anal Biochem. 1998 May 1;258(2):209-15 [9570831.001]
  • [Cites] Genomics. 1997 Nov 1;45(3):607-17 [9367686.001]
  • [Cites] Endocrinology. 2002 Sep;143(9):3376-84 [12193550.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Oct;82(2-3):169-79 [12477483.001]
  • [Cites] Anal Biochem. 2003 Mar 15;314(2):217-26 [12654308.001]
  • [Cites] Endocrinology. 1992 Sep;131(3):1305-12 [1505465.001]
  • [Cites] Mol Endocrinol. 2004 Dec;18(12):2854-65 [15231873.001]
  • [Cites] Trends Endocrinol Metab. 2005 Sep;16(7):320-6 [16054836.001]
  • [Cites] Breast Cancer Res. 2005;7(6):243-4 [16280047.001]
  • [Cites] Endocrinology. 2006 Feb;147(2):662-71 [16293660.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6359-66 [17085646.001]
  • [Cites] Nature. 1977 Jan 6;265(5589):69-72 [834244.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Apr;72(5):249-58 [10822014.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2537-41 [11289127.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):615-23 [11857292.001]
  • [Cites] FEBS Lett. 2002 Apr 10;516(1-3):133-8 [11959119.001]
  • [Cites] Eur J Biochem. 2002 May;269(10):2485-90 [12027886.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):639-50 [12209124.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2434-9 [12750263.001]
  • [Cites] Endocrine. 2003 Nov;22(2):101-12 [14665713.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27008-16 [15090535.001]
  • [Cites] Endocrinology. 2005 Feb;146(2):624-32 [15539556.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2371-4 [9215322.001]
  • [Cites] Trends Endocrinol Metab. 2005 Oct;16(8):362-7 [16125968.001]
  • (PMID = 21655374.001).
  • [Journal-full-title] Breast cancer : basic and clinical research
  • [ISO-abbreviation] Breast Cancer (Auckl)
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3091398
  • [Keywords] NOTNLM ; G protein coupled receptor 30 (GPR30) / breast tumorigenesis / cell surface estrogen receptor and lymph node metastasis / estrogen signaling
  •  go-up   go-down


60. Eum EA, Kim H, Kim YM, Woo SJ, Cho JH, Min YJ, Park JH: Anorectal and gastric peripheral T-cell lymphoma, unspecified in a non-AIDS patient. Korean J Intern Med; 2006 Dec;21(4):262-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anorectum is a rare location for malignant lymphoma.
  • Sigmoidoscopy showed anal and rectal submucosal tumor.
  • He underwent excisional biopsy for the anal mass and the diagnosis was PTCLu.
  • Biopsies of the gastric lesions gave the same diagnosis.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Lymphoma, T-Cell, Peripheral / pathology. Rectal Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Follow-Up Studies. Gastroscopy. Humans. Male. Sigmoidoscopy. Tomography, X-Ray Computed


61. Kulig J, Richter P, Gurda-Duda A, Gach T, Klek S: The role and value of endorectal ultrasonography in diagnosing T1 rectal tumors. Ultrasound Med Biol; 2006 Apr;32(4):469-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role and value of endorectal ultrasonography in diagnosing T1 rectal tumors.
  • The authors evaluated the diagnostic accuracy of the preoperative endorectal ultrasonography (ERUS) in the staging of rectal tumors and the usefulness of the method to assess patients' suitability for local excision.
  • The depth of invasion into the rectal wall was assessed by ERUS and all patients were qualified for tumor excision with transanal endoscopic microsurgery (TEM).
  • Local excision with TEM was deemed to be curative in 86.2% patients with rectal tumors detected by ERUS.
  • ERUS is an accurate method of preoperative assessment of T1 and T2 carcinomas and its diagnostic accuracy is sufficient to qualify patients for anal-saving operations.
  • [MeSH-major] Rectal Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Endosonography. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / ultrasonography. Neoplasm Staging. Proctoscopy. Treatment Outcome. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616592.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Zhai G, Wu J, Xiang G, Mao W, Yu B, Li H, Piao L, Lee LJ, Lee RJ: Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J Nanosci Nanotechnol; 2009 Mar;9(3):2155-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, FR targeted liposomes can potentially enhance tumor cell uptake and antitumor efficacy of encapsulated drugs.
  • FR-targeted liposomes are promising tumor cell-selective nanocarriers for docetaxel with potential for therapeutic applications.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival. Drug Stability. Female. Fluoresceins / metabolism. Fluorescent Dyes / metabolism. Folate Receptors, GPI-Anchored. Freeze Drying. Half-Life. Humans. Liposomes / chemistry. Metabolic Clearance Rate. Mice. Mice, Inbred ICR. Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharm Res. 2004 Dec;21(12):2153-7 [15648245.001]
  • [Cites] Methods Enzymol. 2005;391:97-117 [15721376.001]
  • [Cites] Langmuir. 2005 Mar 15;21(6):2560-8 [15752053.001]
  • [Cites] J Colloid Interface Sci. 2005 May 1;285(1):326-35 [15797430.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1A):343-6 [15816557.001]
  • [Cites] J Drug Target. 2005 Jan;13(1):19-27 [15848951.001]
  • [Cites] J Vasc Interv Radiol. 2005 Oct;16(10):1365-71 [16221908.001]
  • [Cites] J Liposome Res. 2005;15(3-4):157-66 [16393907.001]
  • [Cites] Int J Pharm. 2006 Jun 19;316(1-2):148-53 [16564654.001]
  • [Cites] Int J Pharm. 2007 Mar 21;333(1-2):167-76 [17101248.001]
  • [Cites] Int J Pharm. 2007 May 24;336(2):276-83 [17212981.001]
  • [Cites] J Pharm Pharmacol. 2007 May;59(5):661-7 [17524231.001]
  • [Cites] Int J Pharm. 2007 Jun 29;338(1-2):258-66 [17337138.001]
  • [Cites] Biophys J. 2007 Aug 15;93(4):1204-14 [17526577.001]
  • [Cites] J Pharm Sci. 2007 Sep;96(9):2424-35 [17588260.001]
  • [Cites] Eur Phys J E Soft Matter. 2007 Jul;23(3):247-54 [17619814.001]
  • [Cites] Int J Pharm. 2008 May 22;356(1-2):29-36 [18258394.001]
  • [Cites] Ann Oncol. 1999 Apr;10(4):391-5 [10370780.001]
  • [Cites] Adv Drug Deliv Rev. 2000 Mar 30;41(2):147-62 [10699311.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1590-8 [11527683.001]
  • [Cites] Blood. 2002 Jul 15;100(2):594-602 [12091353.001]
  • [Cites] Bioconjug Chem. 2002 Sep-Oct;13(5):1044-53 [12236787.001]
  • [Cites] Int J Pharm. 2003 Mar 6;253(1-2):121-32 [12593943.001]
  • [Cites] J Control Release. 2003 Sep 4;91(3):417-29 [12932719.001]
  • [Cites] Int Immunopharmacol. 2003 Dec;3(13-14):1699-714 [14636822.001]
  • [Cites] Anal Biochem. 2004 Jan 15;324(2):276-84 [14690692.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6551-9 [14695160.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4927-31 [14981947.001]